U.S. patent application number 17/397287 was filed with the patent office on 2022-02-17 for interleukin-4 receptor-binding fusion proteins and uses thereof.
The applicant listed for this patent is Medicenna Therapeutics Inc., The United States of America, as represented by the Secretary, Department of Health and Human Servic, The United States of America, as represented by the Secretary, Department of Health and Human Servic. Invention is credited to Bharatkumar H. Joshi, Fahar Merchant, Raj K. Puri.
Application Number | 20220048965 17/397287 |
Document ID | / |
Family ID | 1000005940853 |
Filed Date | 2022-02-17 |
United States Patent
Application |
20220048965 |
Kind Code |
A1 |
Merchant; Fahar ; et
al. |
February 17, 2022 |
INTERLEUKIN-4 RECEPTOR-BINDING FUSION PROTEINS AND USES THEREOF
Abstract
The present invention relates to interleukin-4 receptor binding
fusion proteins. More specifically, the invention provides, in
part, fusion proteins that include an interleukin-4 receptor
binding protein moiety joined to a pro-apoptotic Bcl-2 family
member protein moiety.
Inventors: |
Merchant; Fahar; (Vancouver,
CA) ; Puri; Raj K.; (Potomac, MD) ; Joshi;
Bharatkumar H.; (Rockville, MD) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Medicenna Therapeutics Inc.
The United States of America, as represented by the Secretary,
Department of Health and Human Servic |
Toronto
Silver Spring |
MD |
CA
US |
|
|
Family ID: |
1000005940853 |
Appl. No.: |
17/397287 |
Filed: |
August 9, 2021 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
16125075 |
Sep 7, 2018 |
11084856 |
|
|
17397287 |
|
|
|
|
15024785 |
Mar 24, 2016 |
10093708 |
|
|
PCT/CA2014/050915 |
Sep 24, 2014 |
|
|
|
16125075 |
|
|
|
|
61881930 |
Sep 24, 2013 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
C07K 14/4747 20130101;
C12N 5/0636 20130101; A61K 38/2026 20130101; A61K 38/00 20130101;
A61K 38/1761 20130101; C12N 2501/48 20130101; C12N 5/0602 20130101;
C07K 2319/00 20130101; A61K 38/193 20130101; C07K 14/5406 20130101;
C12N 15/63 20130101 |
International
Class: |
C07K 14/54 20060101
C07K014/54; C12N 15/63 20060101 C12N015/63; C12N 5/071 20060101
C12N005/071; C07K 14/47 20060101 C07K014/47; A61K 38/17 20060101
A61K038/17; A61K 38/19 20060101 A61K038/19; A61K 38/20 20060101
A61K038/20; C12N 5/0783 20060101 C12N005/0783 |
Claims
1. A fusion protein comprising an interleukin-4 (1L-4) receptor
binding protein and a pro-apoptotic Bcl-2 family polypeptide
2. The fusion protein of claim 1 wherein the IL-4 receptor binding
protein is circularly permuted (cp).
3. The fusion protein of claim 1 or 2 wherein the pro-apoptotic
Bcl-2 family polypeptide comprises a BH3 domain.
4. The fusion protein of claim 3 wherein the pro-apoptotic Bcl-2
family polypeptide comprising a BH3 domain is Bad, Bik/Nbk, Bid,
Bim/Bod, Hrk, Bak or Bax.
5. The fusion protein of claim 3 or 4 wherein the pro-apoptotic
Bcl-2 family polypeptide comprising a BH3 domain further comprises
a mutation that reduces phosphorylation.
6. The fusion protein of claim 5 wherein the pro-apoptotic Bel-2
family polypeptide comprising a BH3 domain that further comprises a
mutation that reduces phosphorylation is a Bad polypeptide.
7. The fusion protein of any one of claims 1 to 6, wherein the
fusion protein is capable of inhibiting cell survival, inhibiting
cell proliferation, or enhancing cell death or apoptosis of a
target cell expressing an IL-4 receptor (IL-4R).
8. The fusion protein of any one of claims 1 to 7 wherein the IL-4
receptor binding protein is a mutant IL-4 or IL-13 selective for
binding to a Type I or a Type II IL-4R.
9. The fusion protein of claim 8 wherein the mutant IL-4 selective
for binding to a Type II IL-4R comprises a KFR variant or a KF
variant or the mutant IL-4 selective for binding to a Type I IL-4R
comprises an RGA variant.
10. The fusion protein of claim 8 wherein the mutant IL-13
comprises an All variant or a DN variant.
11. The fusion protein of any one of claims 1 to 10 further
comprising a linker.
12. The fusion protein of claim 11 wherein the linker has the
sequence GS or is a ubiquitin or ubiquitin variant molecule.
13. The fusion protein of claim 1 or 2, comprising the amino acid
sequence of any one of SEQ ID NOs: 24-27.
14. A nucleic acid molecule encoding the fusion protein of any one
of claims 1 to 13.
15. A nucleic acid molecule comprising the nucleic acid sequence of
any one of SEQ ID NOs: 35-38.
16. A vector comprising the nucleic acid molecule of claim 14 or
15.
17. A host cell comprising the vector of claim 16.
18. A pharmaceutical composition comprising the fusion protein of
any one of claims 1 to 13, the nucleic acid molecule of claim 14 or
15, the vector of claim 16, or the host cell of claim 17.
19. A method of inducing cell death comprising administering: the
fusion protein of any one of claims 1 to 13, the nucleic acid
molecule of claim 14 or 15, the vector of claim 16, or the host
cell of claim 17, to a subject in need thereof.
20. A method of inducing cell death comprising contacting a target
cell that expresses an IL-4R with the fusion protein of any one of
claims 1 to 13, the nucleic acid molecule of claim 14 or 15, or the
vector of claim 16.
21. A method of treating cancer comprising administering: the
fusion protein of any one of claims 1 to 13, the nucleic acid
molecule of claim 14 or 15, the vector of claim 16, or the host
cell of claim 17, to a subject in need thereof
22. A method of treating cancer comprising contacting a neoplastic
cell that expresses an IL-4R with the fusion protein of any one of
claims 1 to 13, the nucleic acid molecule of claim 14 or 15, or the
vector of claim 16.
23. A method of treating cancer comprising contacting a
non-malignant cell that expresses an IL-4R in a tumour
microenvironment in a subject in need thereof with the fusion
protein of any one of claims 1 to 13, the nucleic acid molecule of
claim 14 or 15, the vector of claim 16, or the host cell of claim
17.
24. The method of claim 23 wherein the non-malignant cell is
contacted prior to said subject starting a therapy.
25. A method of treating a hyperproliferative or differentiative
disorder comprising administering: the fusion protein of any one of
claims 1 to 13, the nucleic acid molecule of claim 14 or 15, the
vector of claim 16, or the host cell of claim 17, to a subject in
need thereof.
26. The method of claim 25 wherein the hyperproliferative or
differentiative disorder is a fibrosis or hyperplasia, an
inflammatory conditions or an autoimmune condition.
27. The method of claim 26 wherein the fibrosis or hyperplasia is
pulmonary fibrosis or hyperplasia (such as benign prostatic
hyperplasia), cardiac fibrosis, or liver fibrosis; the inflammatory
condition is prostatitis, vernal keratoconjunctivitis,
artherosclerosis, or idiopathic pulmonary pneumonia; and the
autoimmune condition is Graves disease.
28. Use of the fusion protein of any one of claims 1 to 13, the
nucleic acid molecule of claim 14 or 15, the vector of claim 16, or
the host cell of claim 17, for inducing cell death or treating
cancer or treating a hyperproliferative or differentiative disorder
in a subject in need thereof.
29. The method of claim 19, 21, 23-27 or the use of claim 28,
wherein the subject is a human.
Description
FIELD OF INVENTION
[0001] The present invention relates to interleukin-4
receptor-binding protein fusions. More specifically, the invention
provides, in part, fusion proteins that include an interleukin-4 or
interleukin-13 protein moiety joined to a pro-apoptotic Bcl-2
family member protein moiety.
REFERENCE TO SEQUENCE LISTING SUBMITTED ELECTRONICALLY
[0002] This disclosure incorporates by reference the Sequence
Listing text copy submitted herewith via EFS-Web, which was created
on Sep. 8, 2021, entitled 117802-5002-US02_Sequence_Listing.txt
which is 67,734 bytes in size.
BACKGROUND OF THE INVENTION
[0003] Interleukin-4 (IL-4) is a pleiotropic cytokine produced by
activated T cells, and is the ligand for the IL-4 receptor (IL-4R),
which can also bind to interleukin-13 (IL-13). IL-4, like many
cytokines, first binds to a high-affinity receptor chain
(designated "a"), followed by binding of the IL-4-a chain complex
with a second low-affinity receptor chain designated "yc".
Therefore, the primary binding chain for IL-4 is the IL-4 receptor
alpha (IL-4Ra), which binds with high affinity
(KD=.about.10-.sup.10 M). The IL-4/1L-4Ra complex can then bind the
second component of the IL-4 receptor, yc (the "Type I" receptor)
with relatively low affinity. Additionally, the IL-4/IL-4Ra complex
can also bind the interleukin-13 (IL-13) receptor al (IL-13R al)
(the "Type II receptor).
[0004] Different cell types express different amounts of the Type 1
and Type 11 receptor chains. For example, while 1L-4Ra is present
on most cells, yc is generally expressed on hematopoietic cells and
IL-13R al is generally expressed on non-hematopoietic cells.
Accordingly, yc, but not IL-13R al, is found on T cells, natural
killer (NK) cells, basophils, mast cells, and most mouse B cells
(most human B cells express both yc and IL-13R al)
[0005] Some bone marrow-derived cells, including macrophages and
dendritic cells, express both yc and IL-13R al and consequently
respond to both IL-4 and IL-13. IL-13R al, but little or no yc, is
found on most non-bone marrow-derived cells, including smooth
muscle and epithelial cells.
[0006] Variant IL-4 molecules having differential selectivities for
Type I and Type II receptors have been proposed (Junttila et al.
Nature Chemical Biology 8:990-998, 2012.)
[0007] Circularly permuted molecules are those in which the termini
of a linear molecule (e.g., ligand) have been joined together,
either directly or via a linker, to produce a circular molecule,
after which the circular molecule is opened at another location to
produce a new linear molecule with termini different from the
termini of the original molecule. Circularly permuted variants of
IL-4 have been described in, for example, U.S. Pat. No. 6,011,002,
issued Jan. 4, 2000, to Pastan el al.
[0008] Programmed cell death or "apoptosis," is a common phenomenon
in the development of animal cells and is both positively and
negatively regulated. In addition to its involvement in neuronal
and lymphoid system development and overall cell population
homeostasis, apoptosis also plays a significant role in various
diseases and injuries resulting from aberrant regulation of
apoptotic pathways. For example, aberrant activation of neuronal
cell death by apoptosis has been implicated in many
neurodegenerative diseases and conditions, such as Alzheimer
disease (Barinaga, Science 281:1303-1304), Huntington's disease,
spinal-muscular atrophy, neuronal damage caused during stroke
(reviewed in Rubin, British Med. Bulle., 53(3):617-631, 1997; and
Barinaga, Science 281:1302-1303), transient ischemic neuronal
injury (e.g., spinal cord injury), etc. Conversely, aberrant
suppression of apoptosis can result in hyperproliferation of cells,
leading to cancer and other hyperproliferative disorders.
[0009] Apoptosis is regulated by a number of proteins, including
members of the Bcl-2 family. Bcl-2 was one of the first proteins
identified as regulating apoptosis (Cleary et al., Cell 47:19-28,
1986; Tsujimoto and Croce, Proc. Natl. Acad. Sci. USA 83:5214-5218,
1986). Since its discovery, several Bcl-2-related proteins ("Bcl-2
family proteins" or "Bcl-2 family members") have been identified as
regulators of apoptosis (White, Genes Dev. 10:1-15, 1996; Yang et
al., Cell 80:285-291, 1995; Lomonosova, E. and G. Chinnadurai,
Oncogene 27, S2S19, 2009).
[0010] Several therapeutic agents for treatment of
neurodegenerative diseases, cancer, etc have been explored but
exhibit limitations that restrict their use in the clinic. For
example, many chemotherapeutic agents act by inducing apoptosis in
proliferating neoplastic cells, but their therapeutic value is
limited by the extent to which they are toxic to normal cells.
Treatment with standard apoptosis inhibitory molecules, for
instance peptide-type caspase inhibitors (e.g., DEVD-type), has
proven unsatisfactory for clinical work due to low membrane
permeability of these inhibitors.
[0011] Targeted immunotoxins (genetic or biochemical fusions
between a toxic molecule, for instance a bacterial toxin, and a
targeting domain derived, typically from an antibody molecule) have
been proposed in attempts to selectively eliminate cancer cells.
For example, diphtheria toxin (DT) variants have been generated and
tested for their ability to selectively kill cancer cells (Thorpe
et al., Nature 271:752-755, 1978; Laske et al., Nature Medicine
3:1362-1368, 1997). Similarly, Pseudomonas exotoxin (PE) fusion
proteins have been investigated as potential cancer therapeutics
(Kreitman and Pastan, Blood 90:252-259, 1997; Shimamura et al.
Cancer Res. 67:9903-9912; 2007).
SUMMARY OF THE INVENTION
[0012] The present invention relates to interleukin-4 receptor
binding fusion proteins. More specifically, the invention provides,
in part, fusion proteins that include a interleukin-4
receptor-binding protein moiety joined to a pro-apoptotic Bcl-2
family member protein moiety and uses thereof
[0013] In one aspect, the invention provides a fusion protein
including a interleukin-4 (IL-4) receptor binding protein and a
pro-apoptotic Bcl-2 family polypeptide. In some embodiments, the
IL-4 receptor binding protein may be circularly permuted (cp). In
some embodiments, the Bcl-2 family polypeptide may be a
pro-apoptotic Bcl-2 family polypeptide comprising a BH3 domain
(such as Bad, Bik/Nbk, Bid, Bim/Bod, Hrk, Bak or Bax). The BH3
domain may further include a mutation that reduces phosphorylation.
The pro-apoptotic Bcl-2 family polypeptide including a BH3 domain
that further includes a mutation that reduces phosphorylation may
be a Bad polypeptide. The fusion protein may be capable of
inhibiting cell survival, inhibiting cell proliferation, or
enhancing cell death or apoptosis of a target cell expressing an
IL-4R.
[0014] In some embodiments, the IL-4 receptor binding protein may
be a mutant IL-4 or IL-13 selective for binding to a Type I or a
Type TT IL-4 receptor (IL-4R) The mutant IL-4 selective for binding
to a Type II IL-4R may include a KFR variant or a KF variant. The
mutant IL-4 selective for binding to a Type I IL-4R may include an
RGA variant. The mutant IL-13 may be an All variant or a DN
variant.
[0015] In some embodiments, the fusion protein may further include
a linker. The linker may have the sequence GS or may be a ubiquitin
or ubiquitin variant molecule. The fusion protein may include the
sequence set forth in SEQ ID NOs: 24-27.
[0016] In some aspects, there is provided a nucleic acid molecule
encoding a fusion protein as described herein, or a vector
including the nucleic acid molecule, or a host cell including the
vector. In some aspects, there is provided a nucleic acid molecule
encoding a fusion protein as set forth in SEQ ID NOs: 24-27 or
comprising SEQ ID NOs: 35-38.
[0017] In some aspects, there is provided a pharmaceutical
composition including a fusion protein as described herein, a
nucleic acid molecule encoding the fusion protein, or a vector
including the nucleic acid molecule, or a host cell including the
vector.
[0018] In some aspects, there is provided a method of inducing cell
death by administering a fusion protein including a pro-apoptotic
Bcl-2 family polypeptide, a nucleic acid molecule encoding the
fusion protein, or a vector including the nucleic acid molecule, or
a host cell including the vector, to a subject in need thereof.
[0019] In some aspects, there is provided a method of inducing cell
death by contacting a target cell that expresses an IL-4R with a
fusion protein including a pro-apoptotic Bcl-2 family polypeptide,
a nucleic acid molecule encoding the fusion protein, or a vector
including the nucleic acid molecule.
[0020] In some aspects, there is provided a method of treating
cancer by administering: a fusion protein including a pro-apoptotic
Bcl-2 family polypeptide, a nucleic acid molecule encoding the
fusion protein, or a vector including the nucleic acid molecule, or
a host cell including the vector, to a subject in need thereof.
[0021] In some aspects, there is provided a method of treating
cancer by contacting a neoplastic cell that expresses an IL-4R with
a fusion protein including a pro-apoptotic Bcl-2 family
polypeptide, a nucleic acid molecule encoding the fusion protein,
or a vector including the nucleic acid molecule.
[0022] In some aspects, there is provided a method of treating
cancer by contacting a non-malignant cell that expresses an IL-4R
in a tumour microenvironment in a subject in need thereof with a
fusion protein including a pro-apoptotic Bcl-2 family polypeptide,
a nucleic acid molecule encoding the fusion protein, or a vector
including the nucleic acid molecule. In some embodiments, the
non-malignant cell is contacted prior to the subject starting a
therapy.
[0023] In some aspects, there is provided a method of treating a
hyperproliferative or differentiative disorder by administering a
fusion protein including a pro-apoptotic Bcl-2 family polypeptide,
a nucleic acid molecule encoding the fusion protein, or a vector
including the nucleic acid molecule to a subject in need thereof.
The hyperproliferative or differentiative disorder may be a
fibrosis or hyperplasia, an inflammatory conditions or an
autoimmune condition. The fibrosis or hyperplasia may be pulmonary
fibrosis or hyperplasia (such as benign prostatic hyperplasia),
cardiac fibrosis, or liver fibrosis; the inflammatory condition may
be prostatitis, vernal keratoconjunctivitis, artherosclerosis, or
idiopathic pulmonary pneumonia; or the autoimmune condition may be
Graves disease.
[0024] In some aspects, there is provided a use of a fusion protein
including a pro-apoptotic Bcl-2 family polypeptide, a nucleic acid
molecule encoding the fusion protein, or a vector including the
nucleic acid molecule for inducing cell death or treating cancer or
treating a hyperproliferative or differentiative disorder in a
subject in need thereof.
[0025] In various embodiments of the alternative aspects, the
subject may be a human.
[0026] This summary does not necessarily describe all features of
the invention.
BRIEF DESCRIPTION OF THE DRAWINGS
[0027] These and other features of the invention will become more
apparent from the following description in which reference is made
to the appended drawings wherein:
[0028] FIG. 1 is an illustration of a cp1L-4BAD (cpIL-4g:s-BADaa)
in a pET 24a expression vector;
[0029] FIG. 2 is a graph showing the effect of cp1L-4BAD
(cpIL-4BADaa) on IL-4Ra positive tumor cell (U 251) viability;
[0030] FIG. 3 is a graph showing the effect of cp1L-4BAD
(cpIL-4BADaa) (squares) on 1L-4Ra positive tumor cell (U 251)
viability in the presence of excess IL-4 (triangles);
[0031] FIG. 4 is a graph showing the effect of cp1L-4BAD
(cpIL-4BADaa) on IL-4Ra positive tumor cell (Daudi cell)
viability;
[0032] FIG. 5 is a graph showing the effect of cp1L-4BAD
(cp1L-4BADaa) (triangles) on IL-41ta positive tumor cell Daudi
viability in the presence of excess IL-4 (squares);
[0033] FIG. 6 is a graph showing the effect of cp1L-4BAD
(cp1L-4BADaa) on the colony number of IL-4Ra positive tumor cells
(U 251);
[0034] FIG. 7 is a graph showing the effect of intratumoural
(squares) and intraperitoneal (triangles) injection of cpIL-4BAD
fusion protein in athymic mice after the development of
subcutaneous glioma tumors with U 251 tumor cells
(circles=controls);
[0035] FIG. 8 is a graph showing the survival of cpIL-4BAD-treated
mice (intratumoural injection group=open diamonds, intraperitoneal
injection group=triangles, controls=solid diamonds);
[0036] FIG. 9 shows an illustration of a pGWO7 E. coli expression
vector;
[0037] FIGS. 10A-F show the nucleic acid (SEQ ID NOs: 29, 30 and
32) and amino sequences (SEQ ID NOs: 18, 19 and 21) of IL-4BAD
(FIGS. 10A and 10B), cpIL-4BAD (FIGS. 10C and 10D) and cpS4-BAD
(FIGS. 10E and 10F) fusion constructs;
[0038] FIGS. 11A-B show the nucleic acid (FIG. 11A; SEQ ID NO: 37)
and amino sequence (FIG. 11B; SEQ ID NO: 26) of a pKFR4-BAD-H6
fusion construct.
DETAILED DESCRIPTION
[0039] The present disclosure provides, in part, a fusion protein
including an IL-4R binding protein joined to a pro-apoptotic Bcl-2
family protein and uses thereof.
[0040] IL-4R Binding Proteins
[0041] IL-4R binding proteins include IL-4 and IL-13.
[0042] IL-4 proteins or IL-4 "protein moieties" include native IL-4
proteins, as well as variant IL-4 proteins. A "native" or "wild
type" IL-4 sequence, as used herein, refers to a human IL-4
sequence, whether purified from natural sources or made using
recombinant techniques, and including the amino acid sequence (with
an additional methionine at the N-terminus) as follows:
TABLE-US-00001 (SEQ ID NO: 1)
MHKCDITLQEIIKTLNSLTEQKTLCTELTVTDIFAASKNTTEKETFCRA
ATVLRQFYSHHEKDTRCLGATAQQFH RH KQURFLKRLDR
NLWGLAGLNSCPVKEANQSTLENFLERLKTEVIREKYSKCSS.
[0043] Alternative human IL-4 sequences include the amino acid
sequence (with an additional methionine at the N-terminus) as
follows:
TABLE-US-00002 (SEQ ID NO: 2)
MHKCDITLQEIIKTLNSLTEQKTLCTELTVTDIFAASKDTTEKETFCRA
ATVLRQFYSHHEKDTRCLGATAQQFH RH KQURFLKRLDRN
LWGLAGLNSCPVKEANQSTLENFLERLKTEVIREKYSKCSS.
[0044] In some embodiments, IL-4 proteins that can be used in the
fusion proteins of the present disclosure are variant IL-4 proteins
that have increased selectivity for yc (Type I receptor) relative
to IL-13R al (Type II receptor) or vice versa as described, for
example, in Junttila et al. (Nature Chemical Biology 8:990-998,
2012). In some embodiments, a variant IL-4 protein that has
increased selectivity for yc (Type I receptor) is an IL-4 protein
that includes the following mutations relative to the sequence of
native human IL-4 (e.g., SEQ ID NO: 1) or an alternative IL-4
sequence (e.g., SEQ ID NO:2), the numbering excluding the
methionine at the N-terminus: R121Q/Y124W/S125F (the "RGA" or
"super-4" or "S4" variant) as described, for example, in Junttila
et al. (Nature Chemical Biology 8:990-998, 2012).
[0045] In some embodiments, a variant IL-4 protein that has
increased selectivity for IL-13R al (Type II receptor) is an IL-4
protein that includes the following mutations relative to the
sequence of native human IL-4 (e.g., SEQ ID NO: 1) or an
alternative IL-4 sequence (e.g., SEQ ID NO:2), the numbering
excluding the methionine at the N-terminus: R121K/Y124F/S125R (the
"KFR" or "KFR4" variant) or R121K/Y124F (the "KF" variant).
[0046] In some embodiments, IL-4 proteins that can be used in the
fusion proteins of the present disclosure are circularly permuted
(cp), as described in, for example, U.S. Pat. No. 6,011,002, issued
Jan. 4, 2000, to Pastan et al. In some embodiments, a cpIL-4
protein that can be used in the fusion proteins of the present
disclosure includes an IL-4 protein in which residues 38-129 of
native human IL-4 (e.g., SEQ ID NO: 1) or an alternative IL-4
sequence (e.g., SEQ ID NO:2), the numbering excluding the
methionine at the N-terminus, are joined to residues 1-37 with a
GGNGG linker and an initial methionine residue, as follows:
TABLE-US-00003 (SEQ ID NO: 3)
MDTTEKETFCRAATVLRQFYSHHEKDTRCLGATAQQFHRHKQURFLKRL
DRNLWGLAGLNSCPVKEANQSTLENFLERLKTIMREKYSKCSSGGNGGH
KCDITLQEIIKTLNSLTEQKTLCTELTVTDIFAAS.
[0047] In alternative embodiments, a cp1L-4 protein that can be
used in the fusion proteins of the present disclosure includes an
IL-4 protein in which residues 38-129 of native human IL-4 (e.g.,
SEQ ID NO: 1) or an alternative IL-4 sequence (e.g., SEQ ID NO:2),
the numbering excluding the methionine at the N-terminus, are
joined to residues 1-37 with a GGNGG linker and an initial
methionine residue, in the context of an "RGA" or "super-4" or "S4"
variant, as follows:
TABLE-US-00004 (SEQ ID NO: 4)
MDTTEKETFCRAATVLRQFYSHHEKDTRCLGATAQQFHRHKQURFLKRL
DRNLWGLAGLNSCPVKEANQSTLENFLERLRVIMQSKWFKCGA
HKCDITLQEIIKTLNSLTEQKTLCTELTVTDIFAAS.
[0048] In alternative embodiments, a cpIL-4 protein that can be
used in the fusion proteins of the present disclosure includes an
IL-4 protein in which residues 38-129 of native human IL-4 (e.g.,
SEQ ID NO: 1) or an alternative IL-4 sequence (e.g., SEQ ID NO:2),
the numbering excluding the methionine at the N-terminus, are
joined to residues 1-37 with a GGNGG linker and an initial
methionine residue, in the context of a "KFR" variant, as
follows:
TABLE-US-00005 (SEQ ID NO: 5)
MDTTEKETFCRAATVLRQFYSHHEKDTRCLGATAQQFHRHKQURFLKRL
DRNLWGLAGLNSCPVKEANQSTLENFLERLKTIMKEKFRKCSS
HKCDITLQEIIKTLNSLTEQKTLCTELTVTDIFAAS.
[0049] In alternative embodiments, a cpIL-4 protein that can be
used in the fusion proteins of the present disclosure includes an
IL-4 protein in which residues 38-129 of native human IL-4 (e.g.,
SEQ ID NO: 1) or an alternative IL-4 sequence (e.g., SEQ ID NO:2),
the numbering excluding the methionine at the N-terminus, are
joined to residues 1-37 with a GGNGG linker and an initial
methionine residue, in the context of a "KF" variant, as
follows:
TABLE-US-00006 (SEQ ID NO: 6)
MDTTEKETFCRAATVLRQFYSHHEKDTRCLGATAQQFHRHKQURFLKRL
DRNLWGLAGLNSCPVKEANQSTLENFLERLKTIMKEKFKCSS
HKCDITLQEIIKTLNSLTEQKTLCTELTVTDIFAAS.
[0050] In alternative embodiments, a cpIL-4 protein that can be
used in the fusion proteins of the present disclosure includes an
IL-4 protein in which residues 105-129 of native human IL-4 (e.g.,
SEQ ID NO: 1) or an alternative IL-4 sequence (e.g., SEQ ID NO:2),
the numbering excluding the methionine at the N-terminus, are
joined to residues 1-104 with a GGNGG linker and an initial
methionine residue, as described in, for example, U.S. Pat. No.
6,011,002, issued Jan. 4, 2000, to Pastan et al.
[0051] Exemplary IL-4 proteins that can be used in the fusion
proteins of the present disclosure include those described herein,
as well as sequences having at least 80% sequence identity, at
least 85%, at least 90%, at least 95%, at least 98% or even at
least 99% sequence identity to native IL-4 ("variant IL-4
proteins"), as long as the variant IL-4 protein retains the ability
to bind the IL-4 receptor, or retains increased selectivity for the
yc (Type I receptor) relative to IL-13R al (Type II receptor) or
vice versa as described, for example, in Junttila et al. (Nature
Chemical Biology 8:990-998, 2012), or retains a desired biological
activity.
[0052] It is to be understood that IL-4 proteins according to the
present disclosure include fragments that can be smaller than the
native 129 amino acid IL-4 protein, as long as the IL-4 protein
fragment retains the ability to bind the IL-4 receptor, or retains
increased selectivity for the yc (Type I receptor) relative to
IL-13R al (Type II receptor) or vice versa as described, for
example, in Junttila et al. (Nature Chemical Biology 8:990-998,
2012), or retains a desired biological activity, whether as a
fragment of the native sequence, or in a cp form or fragment
thereof
[0053] It is also to be understood that the present disclosure
encompasses nucleic acid molecules that encode an IL-4 protein as
described herein or known in the art, including but not limited to
RNA sequences corresponding to the DNA sequences described
herein.
[0054] Exemplary IL-4 nucleic acid molecules include:
TABLE-US-00007 (IL4; SEQ ID NO: 30)
ATGCACAAATGCGACATTACCCTGCAAGAGATCATTAAGACCCTGAACA
GCCTGACCGAGCAAAAGACCCTGTGTACCGAACTGACCGTCACGGACAT
CTTCGCTGCGTCCAAGGACACTACGGAAAAGGAAACGTTCTGTCGTGCG
GCGACGGTGCTGCGCCAGTTCTACAGCCACCATGAGAAAGATACCCGTT
GCCTCGGTGCGACCGCGCAACAGTTCCACCGTCACAAACAGCTGATTCG
CTTCCTGAAGCGTCTGGATCGCAACCTGTGGGGTTTGGCGGGTCTGAAC
TCCTGTCCAGTCAAAGAAGCCAATCAGTCTACGCTGGAAAACTTTTTGG
AGCGTCTGAAAACTATCATGCGTGAGAAGTACAGCAAATGCAGCAGC; (cpIL4; SEQ ID NO:
31) ATGGATACCACCGAGAAAGAAACGTTCTGCCGTGCTGCCACTGTCCTGC
GCCAGTTTTACAGCCATCACGAAAAGGACACCCGTTGCCTGGGTGCGAC
GGCGCAGCAATTCCACCGCCACAAACAGCTGATTCGTTTCCTGAAGCGT
CTGGACCGTAACCTGTGGGGTCTGGCGGGTCTGAACAGCTGTCCAGTGA
AAGAAGCGAATCAGAGCACCTTGGAGAATTTCCTCGAACGCCTGAAAAC
CATCATGCGTGAGAAATACAGCAAGTGTTCTAGCGGCGGTAACGGTGGC
CACAAATGCGATATCACCCTGCAAGAGATCATTAAGACGCTGAACTCCT
TGACGGAACAAAAGACCCTGTGTACTGAGCTGACGGTCACCGACATTTT CGCGGCGTCC; (the
cpKFR; SEQ ID NO: 32)
ATGGATACTACCGAGAAAGAAACGTTTTGCCGTGCTGCGACCGTCCTGC
GTCAGTTCTACAGCCACCACGAAAAGGACACCCGCTGTCTGGGTGCGAC
TGCCCAACAATTCCATCGTCACAAACAGCTGATTCGTTTCCTGAAGCGT
CTGGACCGCAACCTGTGGGGTCTGGCGGGCTTGAACTCCTGCCCAGTCA
AAGAAGCGAACCAAAGCACCCTGGAAAACTTCTTGGAGCGTCTGAAAAC
GATCATGAAAGAGAAGTTCCGCAAGTGTAGCAGCGGTGGTAATGGTGGC
CACAAGTGCGACATTACGCTGCAGGAAATCATTAAGACCCTGAACTCTC
TGACCGAGCAGAAAACCCTCTGTACCGAGCTGACGGTGACGGATATCTT TGCGGCGAGC; and
(cpS4; SEQ ID NO: 33)
ATGGATACCACCGAAAAAGAAACTTTTTGTCGTGCCGCGACTGTCCTGC
GCCAGTTCTACAGCCACCACGAAAAGGACACCCGTTGCCTGGGTGCGAC
CGCTCAACAATTCCATCGCCACAAACAGCTGATTCGTTTCCTGAAACGT
CTGGATCGCAACCTGTGGGGTCTGGCGGGTTTGAACAGCTGTCCAGTCA
AAGAAGCGAACCAGAGCACCCTGGAAAACTTTCTGGAGCGTCTGCGTGT
TATCATGCAGAGCAAGTGGTTCAAGTGCGGTGCGGGTGGCAATGGTGGC
CACAAGTGTGACATTACCTTGCAAGAGATTATCAAAACGCTGAACTCTC
TGACCGAGCAAAAGACGCTGTGCACCGAGCTGACGGTGACGGACATCTT CGCGGCGTCC.
[0055] IL-13 proteins or IL-13 "protein moieties" include native
IL-13 proteins, as well as variant IL-13 proteins. A "native" or
"wild type" IL-13 sequence, as used herein, refers to a human IL-13
sequence, whether purified from natural sources or made using
recombinant techniques, and including the amino acid sequence (with
an additional methionine at the N-terminus) as follows:
TABLE-US-00008 (SEQ ID NO: 7)
MPGPVPPSTALRELIEELVNITQNQKAPLCNGSMVWSINLTAGMYCAAL
ESLINVSGCSAIEKTQRMLSGFCPHKVSAGQFSSLHVRDTKIEVAQFVK
DLLLHLKKLFREGQFN.
[0056] In some embodiments, IL-13 proteins that can be used in the
fusion proteins of the present disclosure are variant IL-13
proteins that have increased selectivity for IL-13Ra1 (type II
receptor) relative wild-type IL-13 protein. For example, the IL-13
variant sequence may include the amino acid sequence (with an
additional methionine at the N-terminus) as follows:
TABLE-US-00009 (the ''All'' variant; SEQ ID NO: 8)
MPGPVPPSTAVRELIEELINITQNQKAPLCNGSMVWSINRTAGMYCAAL
ESLINVSGCSAIEKTQRMLSGFCPHKVSAGQFSSLHVRSSKIEVAQFVK DLLFHLRTLFREG
QFN.
[0057] In some embodiments, a variant IL-13 protein that has
increased selectivity for IL-13Ra1 (type II receptor) relative
wild-type IL-13 protein is an IL-13 protein that includes the
following mutations relative to the sequence of native human IL-13
(SEQ ID NO: 7), the numbering excluding the methionine at the
N-terminus:
L 10V/E12A/V18I/R65D/D87S/T88S/L 101F/K104R/K105T (the "DN"
variant). For example, the IL-13 variant sequence may include the
amino acid sequence (with an additional methionine at the
N-terminus) as follows:
TABLE-US-00010 (SEQ ID NO: 9)
MPGPVPPSTAVRALIEELINITQNQKAPLCNGSMVWSINLTAGMYCA
ALESLINVSGCSAIEKTQDMLSGFCPHKVSAGQFSSLHVRSSKIEVA
QFVKDLLFHLRTLFREGQFN.
[0058] In some embodiments, IL-13 proteins that can be used in the
fusion proteins of the present disclosure are circularly permuted
(cp). In some embodiments, a variant cpIL-13 protein that can be
used in the fusion proteins of the present disclosure includes an
IL-13 protein in which residues 44-114 of native human IL-13 (SEQ
ID NO: 7) are joined to residues 1-43 with a linker and an initial
methionine residue, as follows:
TABLE-US-00011 (SEQ ID NO: 10)
MYCAALESLINVSGCSAIEKTQRMLSGFCPHKVSAGQFSSLHVRDTK
IEVAQFVKDLLLHLKKLFREGQFNGGSGPGPVPPSTALRELIEELVN
ITQNQKAPLCNGSMVWSINLTAG.
[0059] In some embodiments, a variant cpIL-13 protein that can be
used in the fusion proteins of the present disclosure is as
follows:
TABLE-US-00012 (SEQ ID NO: 11)
MYCAALESLINVSGCSAIEKTQRMLSGFCPHKVSAGQFSSLHVRDTK
IEVAQFVKDLLLHLKKLFREGQFN PGPVPPSTALRELIEEL
VNITQNQKAPLCNGSMVWSINLTAG.
[0060] In alternative embodiments, a variant cp1L-13 protein that
can be used in the fusion proteins of the present disclosure
includes an IL-13 protein in which residues 44-114 of native human
IL-13 (SEQ ID NO: 7) are joined to residues 1-43 with a linker and
an initial methionine residue, in the context of the "Al 1"
variant, as follows:
TABLE-US-00013 (SEQ ID NO: 12)
MYCAALESLINVSGCSAIEKTQRMLSGFCPHKVSAGQFSSLHVRSSK
IEVAQFVKDLLFHLRTLFREGQFN PVPPSTAVRELIEEL
INITQNQKAPLCNGSMVWSINRTAG.
[0061] [In some embodiments, a variant cpIL-13 protein that can be
used in the fusion proteins of the present disclosure is as
follows:
TABLE-US-00014 (SEQ ID NO: 13)
MYCAALESLINVSGCSAIEKTQRMLSGFCPHKVSAGQFSSLHVRSSK
IEVAQFVKDLLFHLRTLFREGQFN MPGPVPPSTAVRELIEE
LINITQNQKAPLCNGSMVWSINRTAG.
[0062] In alternative embodiments, a variant cp1L-13 protein that
can be used in the fusion proteins of the present disclosure
includes an IL-13 protein in which residues 44-114 of native human
IL-13 (SEQ ID NO: 7) are joined to residues 1-43 with a linker and
an initial methionine residue, in the context of the "DN" variant,
as follows:
TABLE-US-00015 (SEQ ID NO: 14)
MYCAALESLINVSGCSAIEKTQDMLSGFCPHKVSAGQFSSLHVRSSK
IEVAQFVKDLLFHLRTLFREGQFNGGSGPGPVPPSTAVRALIEELIN
ITQNQKAPLCNGSMVWSINLTAG.
[0063] In some embodiments, a variant cpIL-13 protein that can be
used in the fusion proteins of the present disclosure is as
follows:
TABLE-US-00016 (SEQ ID NO: 15)
MYCAALESLINVSGCSAIEKTQDMLSGFCPHKVSAGQFSSLHVRSSK
IEVAQFVKDLLFHLRTLFREGQFNGGSGMPGPVPPSTAVRALIEELI
NITQNQKAPLCNGSMVWSINLTAG.
[0064] Exemplary IL-13 proteins that can be used in the fusion
proteins of the present disclosure include those described herein,
as well as sequences having at least 80% sequence identity, at
least 85%, at least 90%, at least 95%, at least 98% or even at
least 99% sequence identity to native IL-13 ("variant IL-13
proteins"), as long as the variant IL-13 protein retains the
ability to bind the IL-13 receptor, or retains increased
selectivity for the IL-13Ra1 (type II receptor) relative to
wild-type IL-13 protein, or retains a desired biological
activity.
[0065] It is to be understood that IL-13 proteins according to the
present disclosure include fragments that can be smaller than the
native 114 amino acid IL-13 protein, as long as the IL-13 protein
fragment retains the ability to bind the IL-13 receptor, or retains
increased selectivity for the IL-13Ra1 (type II receptor) relative
to wild-type IL-13 protein, or retains a desired biological
activity.
[0066] It is also to be understood that the present disclosure
encompasses nucleic acid molecules (including but not limited to
RNA sequences or DNA sequences) that encode an IL-13 protein as
described herein or known in the art.
[0067] BCL-2 Family Proteins
[0068] Bcl-2-related proteins or polypeptides ("Bcl-2 family
proteins" or "Bcl-2 family members") are involved in regulation of
apoptosis. Bcl-2 family proteins fall into two distinct categories:
those that inhibit cell death (the "anti-apoptotic" Bcl-2 family
proteins) and those that enhance cell death (the "pro-apoptotic"
Bcl-2 family proteins). Bcl-2 family proteins share one to four
conserved Bcl-2 homology (BH) domains, designated BH1, BH2, BH3,
and BH4.
[0069] Pro-apoptotic Bcl-2 family proteins include those having a
BH3 domain, such as Bad (e.g., Accession no: NP116784, CAG46757 or
Q92934), Bik/Nbk (e.g., Accession no: CAG30276 or Q13323), Bid
(e.g., Accession no: CAG28531 or P55957), Bim/Bod (e.g., Accession
no: NP619527), Hrk (Accession no: 000198), Bak, or Bax. In some
embodiments, pro-apoptotic Bcl-2 family proteins that can be used
in the fusion proteins according to the present disclosure are
mutated (for example at serine residues e.g., serine to alanine
mutations) to prevent phosphorylation.
[0070] Bad, Bcl-2-associated agonist of cell death, is a regulator
of programmed cell death (apoptosis). Bad positively regulates cell
apoptosis by forming heterodimers with Bcl-xL and Bcl-2, and
reversing their death repressor activity. Pro-apoptotic activity of
Bad is regulated through its phosphorylation. Exemplary Bad
proteins that can be used in the fusion proteins of the present
disclosure include those in GenBank Accession Nos. CAG46757;
AAH01901.1; and CAG46733.1, as well as those sequences provided in
U.S. Pat. No. 6,737,511 (sequences herein incorporated by
reference) and described herein, as well as sequences having at
least 80% sequence identity, at least 85%, at least 90%, at least
95%, at least 98% or even at least 99% sequence identity to such
sequences, as long as the variant retains or has enhanced
biological activity of the native Bad protein. In some embodiments,
a Bad protein that can be used in the fusion proteins according to
the present disclosure contains serine mutations at positions 112
and/or 136 to reduce phosphorylation. In some embodiments, a Bad
protein that can be used in the fusion proteins according to the
present disclosure contains serine to alanine mutations at
positions 112 and/or 136 to reduce phosphorylation. In some
embodiments, a Bad protein that can be used in the fusion proteins
according to the present disclosure includes a sequence as follows,
or fragment thereof:
TABLE-US-00017 (SEQ ID NO: 16)
FQIPEFEPSEQEDSSSAERGLGPSPAGDGPSGSGKHHRQAPGLLWDAS
HQQEQPTSSSHEIGGAGAVEIRSRHSSYPAGTEDDEGMGEEPSPFRGR
SRAAPPNLWAAQRYGRELRRMSDEFVDSFKKGLPRPKSAGTATQMRQS
SSWTRVFQSWWDRNLGRGSSAPSQ; (Accession no: NP116784; SEQ ID NO: 18)
FQIPEFEPSEQEDSSSAERGLGPSPAGDGPSGSGKHHRQAPGLLWDAS
HQQEQPTSSSHEIGGAGAVEIRSRHSSYPAGTEDDEGMGEEPSPFRGR
SRSAPPNLWAAQRYGRELRRMSDEFVDSFKKGLPRPKSAGTATQMRQS
SSWTRVFQSWWDRNLGRGSSAPSQ; or (Accession no: CAG46757; SEQ ID NO:
19) FQIPEFEPSEQEDSSSAERGLGPSPAGDGPSGSGKHHRQAPGLLWDAS
HQQEQPTSSSHEIGGAGAVEIRSRHSSYPAGTEDDEGMGEEPSPFRGR
SRSAPPNLWAAQRYGRELRRMSDEFVDSFKKGLPRPKSAGTATQMRQS
SSVVTRVFQSVVVVDRNLGRGSSAPSQ.
[0071] In some embodiments, a Bad protein that can be used in the
fusion proteins according to the present disclosure includes a
variant sequence as follows, or fragment thereof:
TABLE-US-00018 (SEQ ID NO: 17)
FQIPEFEPSEQEDSSSAERGLGPSPAGDGPSGSGKHHRQAPGLLWDAS
HQQEQPTSSSHEIGGAGAVEIRSRHSAYPAGTEDDEGMGEEPSPFRGR
SRAAPPNLWAAQRYGRELRRMSDEFVDSFKKGLPRPKSAGTATQMRQS
SSWTRVFQSWWDRNLGRGSSAPSQ.
[0072] An exemplary Bik/Nbk protein molecule that can be used in
the fusion proteins according to the present disclosure includes a
sequence as follows, or fragment thereof:
TABLE-US-00019 (Accession no: CAG30276; SEQ ID NO: 20)
SEVRPLSRDILMETLLYEQLLEPPTMEVLGMTDSEEDLDPMEDFDSLE
CMEGSDALALRLACIGDEMDVSLRAPRLAQLSEVAMHSLGLAFIYDQT
EDIRDVLRSFMDGFTTLKENIMRFWRSPNPGSVVVSCEQVLLALLLLL
ALLLPLLSGGLHLLLK.
[0073] An exemplary Bid protein molecule that can be used in the
fusion proteins according to the present disclosure includes a
sequence as follows, or fragment thereof:
TABLE-US-00020 (Accession no: CAG28531; SEQ ID NO: 21)
DCEVNNGSSLRDECITNLLVFGFLQSCSDNSFRRELDALGHELPVLAP
QWEGYDELQTDGNRSSHSRLGRIEADSESQEDIIRNIARHLAQVGDSM
DRSIPPGLVNGLALQLRNTSRSEEDRNRDLATALEQLLQAYPRDMEKE
KTMLVLALLLAKKVASHTPSLLRDVFHTTVNFINQNLRTYVRSLARNG MD.
[0074] An exemplary Bim/Bod protein molecule that can be used in
the fusion proteins according to the present disclosure includes a
sequence as follows:
TABLE-US-00021 (Accession no: MP619527; SEQ ID NO: 22)
AKQPSDVSSECDREGRQLQPAERPPQLRPGAPTSLQTEPQGNPEGNHG
GEGDSCPHGSPQGPLAPPASPGPFATRSPLFIFMRRSSLLSRSSSGYF
SFDTDRSPAPMSCDKSTQTPSPPCQAFNHYLSAMASMRQAEPADMRPE
IWIAQELRRIGDEFNAYYARRVFLNNYQAAEDHPRMVILRLLRYIVRL VWRMH.
[0075] An exemplary Hrk protein molecule that can be used in the
fusion proteins according to the present disclosure includes a
sequence as follows:
TABLE-US-00022 (Accession no: 000198; SEQ ID NO: 23)
CPCPLHRGRGPPAVCACSAGRLGLRSSAAQLTAARLKALGDELHQRTM
WRRRARSRRAPAPGALPTYWPWLCAAAQVAALAAWLLGRRN.
[0076] In some embodiments, a pro-apoptotic Bcl-2 family protein
includes at least a fragment of a Bcl-2 family member, where the
pro-apoptotic Bcl-2 family protein or fragment is capable of
inhibiting cell survival, inhibiting cell proliferation, or
enhancing cell death or apoptosis. By "inhibiting cell survival" is
meant decreasing (e.g., by at least 10%, 20%, 30%, or by as much as
50%, 75%, 85% or 90% or more) the probability that a cell at risk
of cell death will survive. By "inhibiting cell proliferation" is
meant decreasing (e.g., by at least 10%, 20%, 30%, or by as much as
50%, 75%, 85% or 90% or more) the growth or proliferation of a
cell. By "enhancing cell death or apoptosis" is meant increasing
(e.g., by at least 10%, 20%, 30%, or by as much as 50%, 75%, 85% or
90% or more) the probability that a cell at risk of cell death will
undergo apoptotic, necrotic, or any other form of cell death.
Suitable assays for measuring the inhibition of cell survival,
inhibition of cell proliferation, or enhancement of cell death or
apoptosis are described herein or known in the art.
[0077] It is also to be understood that the present disclosure
encompasses nucleic acid molecules (e.g., RNA sequences or DNA
sequences) that encode a pro-apoptotic Bcl-2 family member as
described herein, including but not limited to RNA sequences
corresponding to the DNA sequences described herein.
[0078] An exemplary pro-apoptotic Bcl-2 family member nucleic acid
molecule includes:
TABLE-US-00023 (variant BAD; SEQ ID NO: 34)
GGTAGCTTTCAGATCCCGGAATTTGAGCCGAGCGAGCAAGAGGATTCA
AGCAGCGCGGAGCGCGGTCTGGGTCCGAGCCCGGCAGGCGACGGTCCG
AGCGGCAGCGGCAAGCATCACCGCCAGGCGCCAGGCCTGCTGTGGGAT
GCATCGCATCAACAGGAACAACCGACGAGCAGCAGCCATCATGGTGGC
GCTGGTGCGGTTGAGATTAGATCGCGCCACTCCGCATATCCTGCCGGC
ACCGAAGATGACGAAGGCATGGGCGAGGAACCGAGCCCGTTCCGTGGC
CGTAGCCGTGCTGCACCGCCGAATCTGTGGGCCGCACAGCGTTATGGT
CGCGAGTTGCGTCGCATGTCCGACGAGTTTGTTGACTCCTTCAAGAAA
GGTTTACCGCGTCCGAAATCTGCCGGTACCGCGACGCAGATGCGTCAG
AGCAGCAGCTGGACCCGCGTGTTTCAATCTTGGTGGGATCGTAATCTG
GGTCGTGGTAGCAGCGCACCGAGCCAA.
[0079] IL-4 Receptor Binding Protein-Bcl-2 Family Fusion
Proteins
[0080] "Fusion proteins" according to the present disclosure
include IL-4R binding proteins, such as IL-4 and IL-13, joined to a
pro-apoptotic Bcl-2 family member, with optional additional
sequences or moieties (such as linkers), as described herein, as
well as nucleic acid molecules encoding such fusion proteins. Also
encompassed are recombinant nucleic acid molecules in which a
nucleic acid sequence encoding a fusion protein is operably linked
to a promoter, vectors containing such a molecule, and transgenic
cells comprising such a molecule.
[0081] IL-4 (including cp1L-4 and IL-4 fragments and variants) can
be linked to pro-apoptotic Bcl-2 family polypeptides comprising a
BH3 domain as exemplified by Bad, Bik/Nbk, Bid, Bim/Bod, Hrk, Bak,
or Bax or combinations thereof, or fragments or variants thereof,
as long as pro-apoptotic activity is retained. Any form or
derivative of IL-4 can be used. For example, IL-4 or fragments of
IL-4 that bind to the IL-4 receptor can be used. Additionally,
multiple pro-apoptotic Bcl-2 family proteins or fragments or
variants thereof can be joined to 1L-4 or fragments or variants
thereof or multiple 1L-4 proteins or fragments or variants thereof
can be joined to pro-apoptotic Bcl-2 family proteins or fragments
or variants thereof.
[0082] IL-13 (including IL-13 fragments or variants) can be linked
to pro-apoptotic Bcl-2 family polypeptides, for example those
comprising a BH3 domain, as exemplified by Bad, Bik/Nbk, Bid,
Bim/Bod, or Hrk, or combinations thereof, as long as the
combination or fragments or variants thereof retains pro-apoptotic
activity. Any form or derivative of IL-13 can be used. For example,
IL-13 or fragments of IL-13 that bind to the IL-13 receptor can be
used. Additionally, multiple pro-apoptotic Bcl-2 family proteins or
fragments or variants thereof can be joined to IL-13 or fragments
or variants thereof or multiple IL-13 proteins or fragments or
variants thereof can be joined to pro-apoptotic Bcl-2 family
proteins or fragments or variants thereof.
[0083] A cp1L-4, can be linked to pro-apoptotic Bcl-2 family
polypeptides, such as those comprising a BH3 domain as exemplified
by Bad, Bik/Nbk, Bid, Bim/Bod, Hrk, Bak, or Bax or combinations
thereof, or fragments or variants thereof, as long as pro-apoptotic
activity is retained. Any form or derivative of cpIL-4 can be used.
Additionally, multiple cpIL-4 proteins or fragments or variants
thereof, can be joined to a pro-apoptotic Bcl-2 family protein or
fragments or variants thereof, or multiple pro-apoptotic Bcl-2
family proteins or fragments or variants thereof, can be joined to
cp1L-4 proteins or fragments or variants thereof.
[0084] Exemplary fusion proteins are listed in Table 1.
TABLE-US-00024 TABLE 1 IL-4/Bcl-2 Family Fusion Proteins Circularly
permuted Bcl-2 Family Name IL-4 Linker Protein Description IL4-
MHKCDITLQEIIKTLN GS FQIPEFEPSEQED Human IL-4 Bad SLTEQKTLCTELTVT
SSSAERGLGPSP fused to human DIFAASKDTTEKETF AGDGPSGSGKHH Bad
variant CRAATVLRQFYSHH RQAPGLLWDASH via a GS EKDTRCLGATAQQF
QQEQPTSSSHHG linker HRHKQLIRFLKRLDR GAGAVEIRSRHSA NLWGLAGLNSCPVK
YPAGTEDDEGMG EANQSTLENFLERLK EEPSPFRGRSRA TIIVIREKYSKCSS
APPNLWAAQRYG (SEQ ID NO: 2). RELRRMSDEFVD SFKKGLPRPKSAG
TATQMRQSSSVVT RVFQSVWVDRNL GRGSSAPSQ (SEQ ID NO: 17). Fusion Amino
Acid Sequence:
MHKCDITLQEIIKTLNSLTEQKTLCTELTVTDIFAASKDTTEKETFCRAATVLRQFYSHHEK
DTRCLGATAQQFHRHKQURFLKRLDRNLWGLAGLNSCPVKEANQSTLENFLERLKTIM
REKYSKCSSFQIPEFEPSEQEDSSSAERGLGPSPAGDGPSGSGKHHRQAPGLLWDASH
QQEQPTSSSHEGGAGAVEIRSRHSAYPAGTEDDEGMGEEPSPFRGRSRAAPPNLWAA
QRYGRELRRMSDEFVDSFKKGLPRPKSAGTATQMRQSSSWTRVFQSVWVDRNLGRGS SAPSQ
(SEQ ID NO: 24). Fusion DNA Sequence:
ATGCACAAATGCGACATTACCCTGCAAGAGATCATTAAGACCCTGAACAGCCTGACC
GAGCAAAAGACCCTGTGTACCGAACTGACCGTCACGGACATCTTCGCTGCGTCCAA
GGACACTACGGAAAAGGAAACGTTCTGTCGTGCGGCGACGGTGCTGCGCCAGTTCT
ACAGCCACCATGAGAAAGATACCCGTTGCCTCGGTGCGACCGCGCAACAGTTCCAC
CGTCACAAACAGCTGATTCGCTTCCTGAAGCGTCTGGATCGCAACCTGTGGGGTTTG
GCGGGTCTGAACTCCTGTCCAGTCAAAGAAGCCAATCAGTCTACGCTGGAAAACTTT
TTGGAGCGTCTGAAAACTATCATGCGTGAGAAGTACAGCAAATGCAGCAGCGGTAG
CTTTCAGATCCCGGAATTTGAGCCGAGCGAGCAAGAGGATTCAAGCAGCGCGGAGC
GCGGTCTGGGTCCGAGCCCGGCAGGCGACGGTCCGAGCGGCAGCGGCAAGCATC
ACCGCCAGGCGCCAGGCCTGCTGTGGGATGCATCGCATCAACAGGAACAACCGAC
GAGCAGCAGCCATCATGGTGGCGCTGGTGCGGTTGAGATTAGATCGCGCCACTCCG
CATATCCTGCCGGCACCGAAGATGACGAAGGCATGGGCGAGGAACCGAGCCCGTT
CCGTGGCCGTAGCCGTGCTGCACCGCCGAATCTGTGGGCCGCACAGCGTTATGGT
CGCGAGTTGCGTCGCATGTCCGACGAGTTTGTTGACTCCTTCAAGAAAGGTTTACCG
CGTCCGAAATCTGCCGGTACCGCGACGCAGATGCGTCAGAGCAGCAGCTGGACCC
GCGTGTTTCAATCTTGGTGGGATCGTAATCTGGGTCGTGGTAGCAGCGCACCGAGC CAA (SEQ
ID NO: 35). cpl L4-Bad MDTTEKETFCRAAT GS FQIPEFEPSEQED Circularly V
SSSAERGLGPSP permuted LRQFYSHHEKDTRC AGDGPSGSGKHH human IL-4
LGATAQQFHRHKQLI RQAPGLLWDASH fused to RFLKRLDRNLWGLA QQEQPTSSSHHG
human GLNSCPVKEANQSTL GAGAVEIRSRHSA Bad variant ENFLERLKTIMREK
YPAGTEDDEGMG via a GS YSKCSS HKC EEPSPFRGRSRA linker
DITLQEIIKTLNSLTE APPNLWAAQRYG QKTLCTELTVTDI RELRRMSDEFVD FAAS (SEQ
ID NO: 3). SFKKGLPRPKSAG TATQMRQSSSWT RVFQSVWVDRN LGRGSSAPSQ (SEQ
ID NO: 17). Fusion Amino Acid Sequence:
MDTTEKETFCRAATVLRQFYSHHEKDTRCLGATAQQFHRHKWRFLKRLDRNLWGLAGL
NSCPVKEANQSTLENFLERLKTIMREKYSKCSS HKCDITLQEllKTLNSLTEQKTLC
TELTVTDIFAASGSFQIPEFEPSEQEDSSSAERGLGPSPAGDGPSGSGKHHRQAPGLLWDAS
HQQEQPTSSSHEGGAGAVEIRSRHSAYPAGTEDDEGMGEEPSPFRGRSRAAPPNLWAAQ
RYGRELRRMSDEFVDSFKKGLPRPKSAGTATQMRQSSSVVTRVFQSVWVDRNLGRGSSA PSQ
(SEQ ID NO: 25). Fusion DNA Sequence:
ATGGATACCACCGAGAAAGAAACGTTCTGCCGTGCTGCCACTGTCCTGCGCCAGTTTT
ACAGCCATCACGAAAAGGACACCCGTTGCCTGGGTGCGACGGCGCAGCAATTCCACC
GCCACAAACAGCTGATTCGTTTCCTGAAGCGTCTGGACCGTAACCTGTGGGGTCTGGC
GGGTCTGAACAGCTGTCCAGTGAAAGAAGCGAATCAGAGCACCTTGGAGAATTTCCT
CGAACGCCTGAAAACCATCATGCGTGAGAAATACAGCAAGTGTTCTAGCGGCGGTAA
CGGTGGCCACAAATGCGATATCACCCTGCAAGAGATCATTAAGACGCTGAACTAGCT
GGACCCGCGTGTTTCAATCTTGGTGGGATCGTAATCTGGGTCGTGGTAGCAG CGCACCGAGCCAA
(SEQ ID NO: 37). cpS4-Bad MDTTEKETFCRAAT GS FQIPEFEPSEQE Circularly
V DSSSAERGLGPS permuted LRQFYSHHEKDTRCL PAGDGPSGSGKHH RGA
GATAQQFHRHKQLIR RQAPGLLWD (Super-4) FLKRLDRNLWGLAG ASHQQEQPTSSS
variant of L HHGGAGAVEIRS IL-4 fused NSCPVKEANQSTLEN RHSAYPAGTEDD
to pro- FLERLRVIMGKWFK EGMGEEPSPFR apoptotic CGA HKCDIT GRSRAAPPNLW
human Bad L AAQRYGRELRR with GS QEIIKTLNSLTEQKTL MSDEFVDSFKKG
linker; CTELTVTDIFAAS LPRPKSAGTATQMR Mutations in (SEQ ID NO: 4).
QSSSVVTRVF S75A and QSWVVDRNLGRGS S99A of SAPSQ(SEQ ID NO: Bad 17).
Fusion Amino Acid Sequence:
MDTTEKETFCRAATVLRQFYSHHEKDTRCLGATAQQFHRHKQLIRFLKRLDRNLWGLAG
LNSCPVKEANQSTLENFLERLRVIMQSKWFKCGA HKCDITLQEIIKTLNSLTEQK
TLCTELTVTDIFAASGSFQIPEFEPSEQEDSSSAERGLGPSPAGDGPSGSGKHHRQAPG
LLWDASHQQEQPTSSSHHGGAGAVEIRSRHSAYPAGTEDDEGMGEEPSPFRGRSRAA
PPNLWAAQRYGRELRRMSDEFVDSFKKGLPRPKSAGTATQMRQSSSWTRVFQSVWVD
RNLGRGSSAPSQ (SEQ ID NO: 27). Fusion DNA Sequence:
ATGGATACCACCGAAAAAGAAACTTTTTGTCGTGCCGCGACTGTCCTGCGCCAGTTCT
ACAGCCACCACGAAAAGGACACCCGTTGCCTGGGTGCGACCGCTCAACAATTCCATC
GCCACAAACAGCTGATTCGTTTCCTGAAACGTCTGGATCGCAACCTGTGGGGTCTGGC
GGGTTTGAACAGCTGTCCAGTCAAAGAAGCGAACCAGAGCACCCTGGAAAACTTTCT
GGAGCGTCTGCGTGTTATCATGCAGAGCAAGTGGTTCAAGTGCGGTGCGGGTGGCAA
TGGTGGCCACAAGTGTGACATTACCTTGCAAGAGATTATCAAAACGCTGAACTCTCTG
ACCGAGCAAAAGACGCTGTGCACCGAGCTGACGGTGACGGACATCTTCGCGGCGTCC
GGTAGCTTTCAGATCCCGGAATTTGAGCCGAGCGAGCAAGAGGATTCAAGCAGCGCG
GAGCGCGGTCTGGGTCCGAGCCCGGCAGGCGACGGTCCGAGCGGCAGCGGCAAGCA
TCACCGCCAGGCGCCAGGCCTGCTGTGGGATGCATCGCATCAACAGGAACAACCGAC
GAGCAGCAGCCATCATGGTGGCGCTGGTGCGGTTGAGATTAGATCGCGCCACTCCGC
ATATCCTGCCGGCACCGAAGATGACGAAGGCATGGGCGAGGAACCGAGCCCGTTCCG
TGGCCGTAGCCGTGCTGCACCGCCGAATCTGTGGGCCGCACAGCGTTATGGTCGCGA
GTTGCGTCGCATGTCCGACGAGTTTGTTGACTCCTTCAAGAAAGGTTTACCGCGTCCG
AAATCTGCCGGTACCGCGACGCAGATGCGTCAGAGCAGCAGCTGGACCCGCGTGTTT
CAATCTTGGTGGGATCGTAATCTGGGTCGTGGTAGCAGCGCACCGAGCCAA (SEQ ID NO:
38).
[0085] The joining or "fusion" of an IL-4R binding protein, such as
IL-4 or IL-13, to a pro-apoptotic Bcl-2 family member may be
direct, such that one portion of the IL-4R binding protein is
directly attached to a portion of the pro-apoptotic Bcl-2 family
member. For example, one end of the amino acid sequence of an IL-4R
binding protein can be directly attached to an end of the amino
acid sequence of the pro-apoptotic Bcl-2 family member. For
example, the C-terminus of the IL-4R binding protein can be linked
to the N-terminus of the pro-apoptotic Bcl-2 family member, or the
C-terminus of the pro-apoptotic Bcl-2 family member can be linked
to the N-terminus of the IL-4R binding protein. Methods of
generating such fusion proteins are routine in the art, for example
using recombinant molecular biology methods.
[0086] Linkers
[0087] In some embodiments, an IL-4R binding protein moiety can be
linked to the pro-apoptotic Bcl-2 family member moiety indirectly
through a linker. The linker can serve, for example, simply as a
convenient way to link the two moieties, as a means to spatially
separate the two moieties, to provide an additional functionality
to the IL-4R binding protein or the pro-apoptotic Bcl-2 family
member, or a combination thereof
[0088] In general, the linker joining the IL-4R binding protein
moiety and the pro-apoptotic Bcl-2 family member moiety can be
designed to (1) allow the two molecules to fold and act
independently of each other, (2) not have a propensity for
developing an ordered secondary structure which could interfere
with the functional domains of the two moieties, (3) have minimal
hydrophobic or charged characteristics which could interact with
the functional protein domains and/or (4) provide steric separation
of the two regions. For example, in some instances, it may be
desirable to spatially separate the IL-4R binding protein and the
pro-apoptotic Bcl-2 family member to prevent the IL-4R binding
protein from interfering with the activity of the pro-apoptotic
Bcl-2 family member and/or the pro-apoptotic Bcl-2 family member
interfering with the activity of the IL-4R binding protein. The
linker can also be used to provide, for example, lability to the
connection between the IL-4R binding protein and the pro-apoptotic
Bcl-2 family member, an enzyme cleavage site (for example, a
cleavage site for a protease), a stability sequence, a molecular
tag, a detectable label, or various combinations thereof. In some
embodiments, a linker can be present between two domains of an
IL-4R binding protein (such as in a cp molecule) or pro-apoptotic
Bcl-2 family member.
[0089] The linker can be bifunctional or polyfunctional, i.e.,
contain at least about a first reactive functionality at, or
proximal to, a first end of the linker that is capable of bonding
to, or being modified to bond to, the IL-4R binding protein and a
second reactive functionality at, or proximal to, the opposite end
of the linker that is capable of bonding to, or being modified to
bond to, the pro-apoptotic Bcl-2 family member being modified. The
two or more reactive functionalities can be the same (i.e. the
linker is homobifunctional) or they can be different (i.e. the
linker is heterobifunctional).
[0090] The length and composition of a linker can be varied
considerably. The length and composition of the linker are
generally selected taking into consideration the intended function
of the linker, and optionally other factors such as ease of
synthesis, stability, resistance to certain chemical and/or
temperature parameters, and biocompatibility. For example, the
linker should not significantly interfere with the activity of the
IL-4R binding protein and/or pro-apoptotic Bcl-2 family member.
[0091] Linkers suitable for use in a fusion protein according to
the present disclosure include peptides. The linker can be attached
to the IL-4R binding moiety and/or the pro-apoptotic Bcl-2 family
member moiety using recombinant DNA technology. Such methods are
well-known in the art and details of this technology can be found,
for example, in Sambrook, et al. Molecular Cloning: A Laboratory
Manual. 2nd ed., Cold Spring Harbor Laboratory, Cold Spring Harbor
Laboratory Press, Cold Spring Harbor, N.Y., 1989 or Ausubel et al.
Current Protocols in Molecular Biology, John Wiley & Sons,
1994) or updates thereto.
[0092] The linker peptides can have a chain length of 1 to 500
amino acid residues (such as 1 to 100, 1 to 50, 6 to 30, 1 to 40, 1
to 20, or less than 30 amino acids or 5 to 10 amino acids). In some
embodiments, a linker can be 2, 3, 4, 5, 6, 7, or 8 amino acids in
length, or can be about 10, 20, 30, 40 or 50 amino acids in
length.
[0093] Typically, surface amino acids in flexible protein regions
include Gly, Asn and Ser, and such amino acids can be used in
linker sequences. Other neutral amino acids, such as Thr and Ala,
can also be used in the linker sequence. Additional amino acids can
be included in the linker to provide unique restriction sites in
the linker sequence to facilitate construction of the fusions. In
some embodiments, a linker may for instance include the amino acid
sequence Gly-Ser (GS) or may be the amino acid sequence Gly-Ser
(GS) or may include a ubiquitin sequence:
[0094] GGGSM QI FVRTLTGRTITLEVEPSDTI EN VRAR I QDREGI PPDQQRLI
FAGRQLEDGRTLS DYNIQRESTLHLVLRLRGGGS (SEQ ID NO: 28) or variant
thereof. Ubiquitin molecules suitable for use as linkers are
described in, for example, Bachran, C. el al. "Anthrax
toxin-mediated delivery of the Pseudomonas exotoxin A enzymatic
domain to the cytosol of tumor cells via cleavable ubiquitin
fusions MBio. 2013 Apr. 30; 4(3):e00201-13, or in PCT publication
WO/2012/139112.
[0095] Peptide linkers that are susceptible to cleavage by enzymes
of the complement system, urokinase, tissue plasminogen activator,
trypsin, plasmin, or another enzyme having proteolytic activity may
be used in one example. According to another example, the IL-4R
binding protein can be attached via a linker susceptible to
cleavage by enzymes having a proteolytic activity such as a
urokinase, a tissue plasminogen activator, plasmin, thrombin or
trypsin. In addition, the IL-4R binding protein can be attached to
the pro-apoptotic Bcl-2 family member via disulfide bonds (for
example, the disulfide bonds on a cysteine molecule). For example,
in the context of pro-apoptotic Bcl-2 family proteins, since many
tumors naturally release high levels of glutathione (a reducing
agent) this can reduce the disulfide bonds with subsequent release
of the pro-apoptotic Bcl-2 family member at the site of
delivery.
[0096] In some embodiments, a fusion protein according to the
present disclosure may include a pro-apoptotic Bcl-2 family member
and an IL-4R binding protein linked by a cleavable linker region.
In another embodiment, the cleavable linker region can be a
protease-cleavable linker, although other linkers, cleavable for
example by small molecules, may be used. Examples of protease
cleavage sites include those cleaved by factor Xa, thrombin and
collagenase. In one example, the protease cleavage site include
those cleaved by a protease that is associated with a disease. In
another example, the protease cleavage site is one that is cleaved
by a protease that is up-regulated or associated with cancers in
general. Examples of such proteases are uPA, the matrix
metalloproteinase (MiMP) family, the caspases, elastase, prostate
specific antigen (PSA, a serine protease), and the plasminogen
activator family, as well as fibroblast activation protein. In
still another example, the cleavage site is cleaved by a protease
secreted by cancer-associated cells. Examples of these proteases
include matrixmetalloproteases, elastase, plasmin, thrombin, and
uPA. In another example, the protease cleavage site is one that is
up-regulated or associated with a specific cancer. The precise
sequences are available in the art and the skilled person will have
no difficulty in selecting a suitable cleavage site. By way of
example, the protease cleavage region targeted by Factor Xa is
IEGR. The protease cleavage region targeted by enterokinase is
DDDDK. The protease cleavage region targeted by thrombin is LVPRG.
In one example, the cleavable linker region is one which is
targeted by endocellular proteases.
[0097] The linker can be attached to the IL-4R binding protein
moiety and/or pro-apoptotic Bcl-2 family member moiety using
routine techniques as known in the art.
[0098] Preparation of IL-4R Binding Protein/Pro-Apoptotic Bcl-2
Family Fusion Proteins
[0099] Fusion proteins can be prepared using routine methods as
known in the art. Fusion proteins, as well as modifications
thereto, can be made, for example, by engineering the nucleic acid
encoding the fusion protein using recombinant DNA technology or by
peptide synthesis. Modifications to the fusion protein may be made,
for example, by modifying the fusion protein polypeptide itself,
using chemical modifications and/or limited proteolysis.
Combinations of these methods may also be used to prepare the
fusion proteins.
[0100] Methods of cloning and expressing proteins are well-known in
the art, detailed descriptions of techniques and systems for the
expression of recombinant proteins can be found, for example, in
Current Protocols in Protein Science (Coligan, J. E., et al., Wiley
& Sons, New York). Those skilled in the art will understand
that a wide variety of expression systems can be used to provide
the recombinant protein. Accordingly, the fusion proteins can be
produced in a prokaryotic host (e.g., E. coli, A. salmonicida or B.
subtilis) or in a eukaryotic host (e.g., Saccharomyces or Pichia;
mammalian cells, e.g., COS, NIH 3T3, CHO, BHK, 293, or HeLa cells;
or insect cells (baculovirus)). The fusion proteins can be purified
from the host cells using standard techniques known in the art.
[0101] Sequences for various exemplary fusion proteins are provided
in Table 1. Variants and homologs of these sequences can be cloned,
if an alternative sequence is desired, using standard techniques
(see, for example, Ausubel et al., Current Protocols in Molecular
Biology, Wiley & Sons, NY (1997 and updates); Sambrook et al.,
Sambrook, et al. Molecular Cloning: A Laboratory Manual. 2nd ed.,
Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press,
Cold Spring Harbor, N.Y., 1989 or updates thereto). For example,
the nucleic acid sequence can be obtained directly from a suitable
organism, such as Aeromonas hydrophila, by extracting mRNA and then
synthesizing cDNA from the mRNA template (for example by RT-PCR) or
by PCR-amplifying the gene from genomic DNA. Alternatively, the
nucleic acid sequence encoding either the IL-4R binding moiety or
the pro-apoptotic Bcl-2 family moiety can be obtained from an
appropriate cDNA library by standard procedures. The isolated cDNA
is then inserted into a suitable vector, such as a cloning vector
or an expression vector.
[0102] Mutations (if desired) can be introduced at specific,
pre-selected locations by in vitro site-directed mutagenesis
techniques well-known in the art. Mutations can be introduced by
deletion, insertion, substitution, inversion, or a combination
thereof, of one or more of the appropriate nucleotides making up
the coding sequence.
[0103] The expression vector can further include regulatory
elements, such as transcriptional elements, required for efficient
transcription of the fusion protein-encoding sequences. Examples of
regulatory elements that can be incorporated into the vector
include, but are not limited to, promoters, enhancers, terminators,
and polyadenylation signals. Vectors that include a regulatory
element operatively linked to a nucleic acid sequence encoding a
genetically engineered fusion protein can be used to produce the
fusion protein.
[0104] The expression vector may additionally contain heterologous
nucleic acid sequences that facilitate the purification of the
expressed fusion protein, such as affinity tags such (e.g.,
metal-affinity tags, histidine tags, avidin/streptavidin encoding
sequences, glutathione-S-transferase (GST) encoding sequences,
maltose binding protein (MBP) encoding sequences or biotin encoding
sequences). In one example, such tags are attached to the N- or
C-terminus of a fusion protein, or can be located within the fusion
protein. The tags can be removed from the expressed fusion protein
prior to use according to methods known in the art. Alternatively,
the tags can be retained on the fusion protein, providing that they
do not interfere with the ability of the desired activity of the
fusion protein.
[0105] The fusion protein can include one or more linkers, as well
as other moieties, as desired and/or as discussed herein. These can
include a binding region, such as avidin or an epitope, or a tag
such as a polyhistidine tag, which can be useful for purification
and processing of the fusion protein, as well as other linkers as
described herein. In addition, detectable markers can be attached
to the fusion protein, so that the traffic of the fusion protein
through a body or cell can be monitored conveniently. Such markers
include radionuclides, enzymes, fluorophores, chromophores, and the
like.
[0106] One of ordinary skill in the art will appreciate that the
DNA can be altered in numerous ways without affecting the
biological activity of the encoded protein. For example, PCR can be
used to produce variations in the DNA sequence which encodes a
fusion protein. Such variations in the DNA sequence encoding a
fusion protein can be used to optimize for codon preference in a
host cell used to express the protein, or may contain other
sequence changes that facilitate expression.
[0107] A covalent linkage of an IL-4R binding protein directly to a
pro-apoptotic Bcl-2 family member or via a linker may take various
forms as is known in the art. For example, the covalent linkage may
be in the form of a disulfide bond. The DNA encoding one of the
components can be engineered to contain a unique cysteine codon.
The second component can be derivatized with a sulfhydryl group
reactive with the cysteine of the first component. Alternatively, a
sulfhydryl group, either by itself or as part of a cysteine
residue, can be introduced using solid phase polypeptide
techniques. For example, the introduction of sulfhydryl groups into
peptides is described by Hiskey (Peptides 3:137, 1981).
[0108] Assays
[0109] Fusion proteins can be assayed using standard techniques
known in the art or described herein.
[0110] For example, the ability of the fusion proteins to kill or
inhibit growth of cells can be assayed in vitro using suitable
cells, typically a cell line expressing the target or a cancer
cell. In general, cells of the selected test cell line are grown to
an appropriate density and the candidate fusion protein is added.
The fusion protein can be added to the culture at around at least 1
ng/mL, at least 1 ug/mL, or at least 1 mg/mL, such as from about
0.01 ug/mL to about 1 mg/mL, from about 0.10 ug/mL to about 0.5
mg/mL, from about 1 ug/mL to about 0.4 mg/mL. In some examples,
serial dilutions are tested. After an appropriate incubation time
(for example, about 48 to 72 hours), cell survival or growth is
assessed. Methods of determining cell survival are well known in
the art and include, but are not limited to, the resazurin
reduction test (see Fields & Lancaster Am. Biotechnol. Lab.,
11:48-50, 1993; O'Brien et al., Eur. J. Biochem., 267:5421-5426,
2000 or U.S. Pat. No. 5,501,959), the sulforhodamine assay
(Rubinstein et al., J. Natl. Cancer Inst., 82:113-118, 1999) or the
neutral red dye test (Kitano et al., Euro. J. Clin. Investg.,
21:53-58, 1991; West et al., J. Investigative Derm., 99:95-100,
1992) or trypan blue assay. Numerous commercially available kits
may also be used, for example the CellTiter 96.RTM.AQueous One
Solution Cell Proliferation Assay (Promega). Cytotoxicity is
determined by comparison of cell survival in the treated culture
with cell survival in one or more control cultures, for example,
untreated cultures and/or cultures pre-treated with a control
compound (typically a known therapeutic), or other appropriate
control.
[0111] Additional assays are described in, for example, Crouch et
al. (J. Immunol. Meth. 160, 81-8); Kangas et al. (Med. Biol. 62,
338-43, 1984); Lundin et al., (Meth. Enzymol. 133, 27-42, 1986);
Petty et al. (Comparison of J. Biolum. Chemilum. 10, 29-34, 1995);
and Cree et al. (AntiCancer Drugs 6: 398-404, 1995). Cell viability
can be assayed using a variety of methods, including MTT
(3-(4,5-dimethylthiazolyl)-2,5-diphenyltetrazolium bromide)
(Barltrop, Bioorg. & Med. Chem. Lett. 1: 611, 1991; Cory et
al., Cancer Comm. 3, 207-12, 1991; Paull J. Heterocyclic Chem. 25,
911, 1988). Assays for cell viability are also available
commercially. These assays include but are not limited to
CELLTITER-GLO.RTM. Luminescent Cell Viability Assay (Promega),
which uses luciferase technology to detect ATP and quantify the
health or number of cells in culture, and the Cell Titer-Glo.RTM.
Luminescent Cell Viability Assay, which is a lactate dehyrodgenase
(LDH) cytotoxicity assay (Promega).
[0112] Fusion proteins that confer selectivity for a specific type
of cancer may be tested for their ability to target that specific
cancer cell type. For example, a fusion protein comprising a
specific IL-4 that targets cells displaying IL-4R Type I or Type II
can be assessed for its ability to selectively target such cells by
comparing the ability of the fusion protein to kill cancer cells to
its ability to kill a normal cell, or a different type of cancer
cell (e.g., one that does not express IL-4R Type I or Type II).
Alternatively, flow cytometric methods, as are known in the art,
may be used to determine if a fusion protein comprising a Type I or
Type II receptor-specific IL-4 is able to selectively target a
specific type of cell. Binding of a labeled antibody to the bound
fusion protein will indicate binding of the fusion protein to the
target.
[0113] Similarly, assays for measuring cell apoptosis are known in
the art. Apoptotic cells are characterized by characteristic
morphological changes, including chromatin condensation, cell
shrinkage and membrane blebbing, which can be clearly observed
using light microscopy. The biochemical features of apoptosis
include DNA fragmentation, protein cleavage at specific locations,
increased mitochondria] membrane permeability, and the appearance
of phosphatidylserine on the cell membrane surface. Assays for
apoptosis are known in the art. Exemplary assays include TUNEL
(Terminal deoxynucleotidyl Transferase Biotin-dUTP Nick End
Labeling) assays, caspase activity (specifically caspase-3) assays,
and assays for fas-ligand and annexin V. Commercially available
products for detecting apoptosis include, for example, Apo-ONE.RTM.
Homogeneous Caspase-3/7 Assay, FragEL TUNEL kit (ONCOGENE RESEARCH
PRODUCTS, San Diego, Calif.), the ApoBrdU DNA Fragmentation Assay
(BIOVISION, Mountain View, Calif.), and the Quick Apoptotic DNA
Ladder Detection Kit (BIOVISION, Mountain View, Calif.).
[0114] A variety of cell lines suitable for testing the candidate
fusion proteins are known in the art and many are commercially
available (for example, from the American Type Culture Collection,
Manassas, Va.). Similarly, animal models are known in the art and
many are commercially available.
[0115] Therapeutic Indications and Uses
[0116] The fusion proteins including IL-4R binding protein and a
pro-apoptotic Bcl-2 family member, as described herein, can be used
for a variety of therapeutic purposes. In general, the fusion
proteins described herein can be used in the treatment or
prophylaxis of any disease, disorder or condition which involves
cells which express an IL-4R, and which would be benefited by
inhibiting cell proliferation or enhancing cell death. In some
embodiments, the fusion proteins described herein can be used in
the treatment or prophylaxis of any disease, disorder or condition
which involves cells which express a Type I or Type II IL-4R, and
in which selection of one type of receptor over the other is
useful, and which would be benefited by inhibiting cell
proliferation or enhancing cell death.
[0117] In some embodiments, a fusion protein including a
pro-apoptotic Bcl-2 family member can be used to induce apoptosis
or cell death or to treat a disorder associated with abnormal
apoptosis or cell proliferation, such as cancer. As used herein,
the terms "cancer," "cancerous," "hyperproliferative," or
"neoplastic" refer to cells having the capacity for autonomous
growth (e.g., an abnormal state or condition characterized by
rapidly proliferating cell growth). Hyperproliferative and
neoplastic disease states may be categorized as pathologic (e.g.,
as a deviation from normal but not associated with a disease
state). Accordingly, by a "cancer" or "neoplasm" is meant any
unwanted growth of cells serving no physiological function. In
general, a cell of a neoplasm has been released from its normal
cell division control, i.e., a cell whose growth is not regulated
by the ordinary biochemical and physical influences in the cellular
environment. In most cases, a neoplastic cell proliferates to form
a clone of cells which are either benign or malignant. Examples of
cancers or neoplasms include, without limitation, transformed and
immortalized cells, tumours, and carcinomas such as breast cell
carcinomas and prostate carcinomas. The term cancer includes cell
growths that are technically benign but which carry the risk of
becoming malignant. By "malignancy" is meant an abnormal growth of
any cell type or tissue. The term malignancy includes cell growths
that are technically benign but which carry the risk of becoming
malignant. This term also includes any cancer, carcinoma, neoplasm,
neoplasia, or tumor. The terms are therefore meant to include all
types of cancerous growths or oncogenic processes, metastatic
tissue or malignantly transformed cells, tissues or organs,
irrespective of hi stopathologic type or stage of invasiveness. In
some embodiments, a fusion protein including a pro-apoptotic Bcl-2
family member is not used in connection with a cancer affecting a
stem cell.
[0118] Most cancers fall within three broad histological
classifications: carcinomas, which are the predominant cancers and
are cancers of epithelial cells or cells covering the external or
internal surfaces of organs, glands, or other body structures
(e.g., skin, uterus, lung, breast, prostate, stomach, bowel), and
which tend to metastasize; sarcomas, which are derived from
connective or supportive tissue (e.g., bone, cartilage, tendons,
ligaments, fat, muscle); and hematologic tumors, which are derived
from bone marrow and lymphatic tissue. Examples of cancers include,
without limitation, carcinomas, sarcomas, and hematopoietic
neoplastic disorders e.g., leukemia.
[0119] Carcinomas may be adenocarcinomas (which generally develop
in organs or glands capable of secretion, such as breast, lung,
colon, prostate or bladder) or may be squamous cell carcinomas
(which originate in the squamous epithelium and generally develop
in most areas of the body).
[0120] Sarcomas may be osteosarcomas or osteogenic sarcomas (bone),
chondrosarcomas (cartilage), leiomyosarcomas (smooth muscle),
rhabdomyosarcomas (skeletal muscle), mesothelial sarcomas or
mesotheliomas (membranous lining of body cavities), fibrosarcomas
(fibrous tissue), angiosarcomas or hemangioendotheliomas (blood
vessels), liposarcomas (adipose tissue), gliomas or astrocytomas
(neurogenic connective tissue found in the brain), myxosarcomas
(primitive embryonic connective tissue), or mesenchymous or mixed
mesodermal tumors (mixed connective tissue types).
[0121] Hematopoietic neoplastic disorders include diseases
involving hyperplastic/neoplastic cells of hematopoietic origin
e.g., arising from myeloid, lymphoid or erythroid lineages or
precursor cells thereof. Preferably, the diseases arise from poorly
differentiated acute leukemias (e.g., erythroblastic leukemia and
acute megakaryoblastic leukemia). Additional exemplary myeloid
disorders include, but are not limited to, acute promyeloid
leukemia (APML), acute myeloenous leukemia (AML) and chronic
myeloenous leukemia (CML); lymphoid malignancies include but are
not limited to acute lymphoblastic leukemia (ALL), which includes
B-lineage ALL and T-lineage ALL, chronic lymphocytic leukemia
(CLL), prolymphocytic leukemia (PLL), hairy cell leukemia, and
Waldenstrom's macroglobulinemia.
[0122] Additional forms of malignant lymphomas include, but are not
limited to non-Hodgkin lymphoma and variants thereof, peripheral T
cell lymphomas, adult T cell leukemia/lymphoma (ATL), cutaneous T
cell lymphoma (CTCL), large granular lymphocytic leukemia (LGF),
Hodgkin's disease and Reed-Stemberg disases.
[0123] Cancers may also be named based on the organ in which they
originate i.e., the "primary site," for example, cancer of the
breast, brain, lung, liver, skin, prostate, testicle, bladder,
colon and rectum, cervix, uterus, etc. This naming persists even if
the cancer metastasizes to another part of the body, that is
different from the primary site. Cancers named based on primary
site may be correlated with histological classifications. For
example, lung cancers are generally small cell lung cancers or
non-small cell lung cancers, which may be squamous cell carcinoma,
adenocarcinoma, or large cell carcinoma; skin cancers are generally
basal cell cancers, squamous cell cancers, or melanomas. Lymphomas
may arise in the lymph nodes associated with the head, neck and
chest, as well as in the abdominal lymph nodes or in the axillary
or inguinal lymph nodes. Identification and classification of types
and stages of cancers may be performed by using for example
information provided by the Surveillance, Epidemiology, and End
Results (SEER) Program of the National Cancer Institute.
[0124] In some embodiments, a fusion protein including a
pro-apoptotic Bcl-2 family protein member, or a fragment thereof,
can be used to treat cancers such as gastric carcinoma, invasive
pituitary adenomas, biliary tract carcinoma, cervical cancer,
lymphoma, melanoma, chronic lymphocytic leukemia, non-hodgkins
lymphoma, follicular lymphoma, pancreatic cancer, colorectal
cancer, colon cancer, thyroid cancer, liver cancer, ovarian cancer,
prostate cancer, bladder cancer, renal cell carcinoma,
mesothelioma, rhabdomyosarcoma, breast cancer, non-small cell lung
cancer, head and neck cancers, or Kaposi's carcinoma.
[0125] In some embodiments, a fusion protein including a
pro-apoptotic Bcl-2 family protein member, or a fragment thereof,
can be used to treat CNS cancers such as gliomas, meningeal
tumours, diffuse intrinsic pontine glioma, medulloblastoma,
neuroblastoma, anaplastic astrocytoma, glioblastoma multiforme,
metastatic brain cancer, or CNS lymphoma.
[0126] The fusion proteins can be used to treat, stabilize or
prevent cancer. Fusion proteins can also be used in the treatment
of indolent cancers, recurrent cancers including locally recurrent,
distantly recurrent and/or refractory cancers (i.e. cancers that
have not responded to other anti-cancer treatments), metastatic
cancers, locally advanced cancers and aggressive cancers. In these
contexts, the fusion proteins may exert either a cytotoxic or
cytostatic effect resulting in, for example, a reduction in the
number or growth of cancer cells, a reduction in the size of a
tumor, the slowing or prevention of an increase in the size of a
tumor, an increase in the disease-free survival time between the
disappearance or removal of a tumor and its reappearance,
prevention of an initial or subsequent occurrence of a tumor (e.g.
metastasis), an increase in the time to progression, reduction of
one or more adverse symptoms associated with a tumor, or an
increase in the overall survival time of a subject having
cancer.
[0127] Other examples of proliferative and/or differentiative
disorders that can be treated using a fusion protein including a
pro-apoptotic Bcl-2 family member include proliferative
non-malignant diseases such as pulmonary fibrosis or hyperplasia
(such as benign prostatic hyperplasia), cardiac fibrosis, or liver
fibrosis; inflammatory conditions such as prostatitis, vernal
keratoconjunctivitis, artherosclerosis, idiopathic pulmonary
pneumonia; or autoimmune conditions such as Graves disease.
[0128] In some embodiments, a fusion protein including a
pro-apoptotic Bcl-2 family protein member, or a fragment thereof,
is capable of inhibiting cell survival, inhibiting cell
proliferation, or enhancing cell death or apoptosis. In some
embodiments, the IL-4R binding protein-pro-apoptotic Bcl-2 family
fusion protein is capable of inhibiting cell survival, inhibiting
cell proliferation, or enhancing cell death or apoptosis, when
compared to a suitable control, such as IL-4 alone, IL-4 joined to
a non-pro-apoptotic Bcl-2 family protein, etc. A suitable control
may also include a previously-established standard. Accordingly,
any test or assay for determining the activity or efficacy of an
IL-4R binding protein-pro-apoptotic Bcl-2 family fusion protein may
be compared to the established standard and it may not be necessary
to include a control for comparison each time. By "inhibiting cell
survival" is meant decreasing (e.g., by at least 10%, 20%, 30%, or
by as much as 50%, 75%, 85% or 90% or more) the probability that a
cell at risk of cell death will survive. By "inhibiting cell
proliferation" is meant decreasing (e.g., by at least 10%, 20%,
30%, or by as much as 50%, 75%, 85% or 90% or more) the growth or
proliferation of a cell. By "enhancing cell death or apoptosis" is
meant increasing (e.g., by at least 10%, 20%, 30%, or by as much as
50%, 75%, 85% or 90% or more) the probability that a cell at risk
of cell death will undergo apoptotic, necrotic, or any other form
of cell death.
[0129] In some embodiments, a fusion protein including a
pro-apoptotic Bcl-2 family protein member, or a fragment thereof,
is capable of inhibiting cell survival, inhibiting cell
proliferation, or enhancing cell death or apoptosis by at least
20%, 30%, or by as much as 50%, 75%, 85% or 90% or more, when
compared to a cell cultured under similar conditions but not
contacted with the fusion protein. Suitable assays for measuring
the inhibition of cell survival, inhibition of cell proliferation,
or enhancement of cell death or apoptosis are described herein or
known in the art.
[0130] In some embodiments, the IC5o of a fusion protein including
a pro-apoptotic Bcl-2 family protein member, or a fragment thereof,
in inhibiting cell survival, inhibiting cell proliferation, or
enhancing cell death or apoptosis, can be in the range from about
0.1 ng/mL to about 10,000 ng/mL, or any value therebetween, such as
about 0.5 ng/mL, 1 ng/mL, 5 ng/mL, 10 ng/mL, 25 ng/mL, 50 ng/mL, 75
ng/mL, 100 ng/mL, 150 ng/mL, 200 ng/mL, 250 ng/mL, 300 ng/mL, 350
ng/mL, 400 ng/mL, 450 ng/mL, 500 ng/mL, 550 ng/mL, 600 ng/mL, 650
ng/mL, 700 ng/mL, 750 ng/mL, 800 ng/mL, 850 ng/mL, 900 ng/mL, 950
ng/mL, or 1000 ng/mL.
[0131] "Target cells" include, without limitation, neurons,
lymphocytes, stem cells, epithelial cells, cancer cells, neoplasm
cells, immune cells, non-malignant cells of the tumour
microenvironment, hyper-proliferative cells, etc. The target cell
chosen will depend on the disease or injury or condition the fusion
protein is intended to treat.
[0132] Pharmaceutical Compositions, Dosages and Administration
[0133] Pharmaceutical compositions according to the present
disclosure can include one or more fusion proteins and one or more
non-toxic, pharmaceutically-acceptable carriers, diluents,
excipients and/or adjuvants. Such compositions can be suitable for
use in treatment of therapeutic indications as described
herein.
[0134] If desired, other active ingredients may be included in the
compositions. Accordingly, in some embodiments, a fusion protein
including a pro-apoptotic Bcl-2 family member can be administered
in therapeutically-effective amounts together with one or more
anti-cancer or other therapeutics. The fusion protein(s) can be
administered before, during or after treatment with the anti-cancer
or other therapeutic. An "anti-cancer therapeutic" is a compound,
composition, or treatment (e.g., surgery) that prevents or delays
the growth and/or metastasis of cancer cells. Such anti-cancer
therapeutics include, but are not limited to, surgery (e.g.,
removal of all or part of a tumor), chemotherapeutic drug
treatment, radiation, gene therapy, hormonal manipulation,
immunotherapy (e.g., therapeutic antibodies and cancer vaccines)
and antisense or RNAi oligonucleotide therapy. Examples of useful
chemotherapeutic drugs include, but are not limited to,
hydroxyurea, busulphan, cisplatin, carboplatin, chlorambucil,
melphalan, cyclophosphamide, Ifosfamide, danorubicin, doxorubicin,
epirubicin, mitoxantrone, vincristine, vinblastine, vinorelbine,
etoposide, teniposide, paclitaxel, docetaxel, gemcitabine,
cytosine, arabinoside, bleomycin, neocarcinostatin, suramin, taxol,
mitomycin C, Avastin, Herceptin.RTM., fluorouracil, temozolamide,
etc. The fusion protein(s) are also suitable for use with standard
combination therapies employing two or more chemotherapeutic
agents. It is to be understood that anti-cancer therapeutics
includes novel compounds or treatments developed in the future.
[0135] The fusion protein can also be administered in combination
with a sensitizing agent, such as a radio-sensitizer (see for
example Diehn et al., J. Natl. Cancer Inst. 98:1755-7, 2006).
Generally a sensitizing agent is any agent that increases the
activity of a fusion protein. For example, a sensitizing agent will
increase the ability of a fusion protein to inhibit cancer cell
growth or kill cancer cells. Exemplary sensitizing agents include
antibodies to IL-10, bone morphogenic proteins and HDAC inhibitors
(see for example Sakariassen et al., Neoplasia 9(11):882-92, 2007).
These sensitizing agents can be administered before or during
treatment with the fusion protein. Exemplary dosages of such
sensitizing agents include at least 1 ug/mL, such as at least 10
ug/mL, at least 100 ug/mL, for example 5-100 ug/mL or 10-90 ug/mL.
The sensitizing agents can be administered daily, three times a
week, twice a week, once a week or once every two weeks.
Sensitizing agents can also be administered after treatment with
the fusion protein is finished.
[0136] The fusion proteins may be used as part of a neo-adjuvant
therapy (to primary therapy), as part of an adjuvant therapy
regimen, where the intention is to cure the cancer in a subject.
The fusion proteins can also be administered at various stages in
tumor development and progression, including in the treatment of
advanced and/or aggressive neoplasias (e.g., overt disease in a
subject that is not amenable to cure by local modalities of
treatment, such as surgery or radiotherapy), metastatic disease,
locally advanced disease and/or refractory tumors (e.g., a cancer
or tumor that has not responded to treatment). "Primary therapy"
refers to a first line of treatment upon the initial diagnosis of
cancer in a subject. Exemplary primary therapies may involve
surgery, a wide range of chemotherapies and radiotherapy. "Adjuvant
therapy" refers to a therapy that follows a primary therapy and
that is administered to subjects at risk of relapsing. Adjuvant
systemic therapy is begun soon after primary therapy, for example
2, 3, 4, 5, or 6 weeks after the last primary therapy treatment to
delay recurrence, prolong survival or cure a subject. As discussed
herein, it is contemplated that the fusion proteins can be used
alone or in combination with one or more other chemotherapeutic
agents as part of an adjuvant therapy. Combinations of the fusion
proteins and standard chemotherapeutics may act to improve the
efficacy of the chemotherapeutic and, therefore, can be used to
improve standard cancer therapies. This application can be
particularly important in the treatment of drug-resistant cancers
which are not responsive to standard treatment.
[0137] In cancer, the microenvironment of a tumor contains both
malignant and non-malignant cells. The tumor microenvironment can
be identified using one or more of the following criteria: (a) a
region comprising non-malignant cells which share the same
physiological environment, or which are directly adjacent to
malignant cells; (b) the extended tumor region; (c) an area of
inflammation surrounding or proximal to a tumor; (d) an area in
which the number or rate of proliferation of regulatory T cells is
elevated; and (e) an area in which tumor-associated macrophages,
dendritic cells, myeloid-derived suppressor cells, Th2 cells or
fibrocytes are elevated. Within the context of non-solid tumor
types, the tumor microenvironment may also be determined by the
local cell-cell interactions between malignant cells and between
malignant cells and any adjacent or nearby non-malignant cells.
Such interactions may include, for example, cell adhesion events
and/or paracrine effects of soluble mediators produced by one cell
(malignant or non-malignant) on another cell (malignant or
non-malignant) in the tumor microenvironment.
[0138] The non-malignant cells in the tumor microenvironment can be
important for tumor initiation and progression (Reynolds et al.,
Cancer Res., 1996, 56(24):5754-5757). The non-malignant cells, also
called stromal cells, occupy or accumulate in the same cellular
space as malignant cells, or the cellular space adjacent or
proximal to malignant cells, which modulate tumor cell growth or
survival. For example, non-malignant cells that normally function
to support inflammatory and immune response can be capable of
contributing to tumor initiation or progression. Accordingly, in
alternative embodiments, a fusion protein including a pro-apoptotic
Bcl-2 family member can be used for inhibiting cell survival,
inhibiting cell proliferation, or enhancing cell death or apoptosis
of a non-malignant cell that expresses a Type I or Type II IL-4R in
a tumour microenvironment. Such non-malignant cells can be
immunoregulatory or inflammatory cells such as antigen presenting
cells (e.g., macrophages, dendritic cells, B cells) or
myeloid-derived suppressor cells (e.g., myeloid-derived monocytes
and tie-2-expressing monocytes) present within the tumor
microenvironment, and inhibition of T cell subsets that function to
support tumor progression (e.g., regulatory T cells and Th2 helper
cells) and/or suppressing production of one or more inflammatory
cytokines in a tumor microenvironment. Among the non-malignant
cells of a tumor microenvironment are regulatory T cells, which are
observed in higher frequencies in a number of tumors, including
Hodgkin's lymphoma, non-Hodgkin's lymphoma (Shi et al., Ai Zheng.,
2004, 23(5):597-601 (abstract only)), malignant melanoma (Viguier
et al., J. Immunol., 2004, 173(2):1444-53; Javia et al., J.
Immunother., 2003, 26(1):85-93), and cancers of the ovary (Woo et
al., Cancer Res., 2001, 61(12):4766-72), gastrointestinal tract
(Ichihara et al., Clin Cancer Res., 2003, 9(12):4404-4408; Sasada
et al., Cancer, 2003, 98(5):1089-1099), breast (Liyanage et at., J
Immunol., 2002, 169(5):2756-2761), lung (Woo et al., Cancer Res.,
2001, 61(12):4766-72), and pancreas (Liyanage et al., J Immunol.,
2002, 169(5):2756-2761). The regulatory T cells are recruited to
the tumor site in response to chemokines secreted by the tumor
cells. See e.g., Curiel et al., Nat. Med., 2004, 10:942-949. An
increase in the number of regulatory T cells may also correlate
with poor prognosis (Curiel et al., Nat. Med 2004, 10:942-949;
Sasada et al., Cancer, 2003, 98:1089-1099). Conversely, regulatory
T cells are observed to decrease following chemotherapy (Beyer et
al., Blood, 2005, 106:2018-2025). The tumour micro-environment can
also have a higher proportion of Th2 cells, when compared to Th1
cells, which is associated with poor prognosis and survival. In
alternative embodiments, a fusion protein including a pro-apoptotic
Bcl-2 family member according to the invention, such as cpIL-4-Bad,
is useful for restoring the Th1>>Th2 balance by, for example,
depleting Th2 cells. In some embodiments, a fusion protein
including a pro-apoptotic Bcl-2 family member according to the
invention, such as cpIL-4-Bad, may be administered to a subject
prior to, or during, chemotherapy, radiation therapy,
immunotherapy, etc. to disable or downregulate the tumor
microenvironment.
[0139] Non-malignant cells can also be fibroblasts, myofibroblasts,
glial cells, epithelial cells, adipocytes, vascular cells
(including blood and lymphatic vascular endothelial cells and
pericytes), resident and/or recruited inflammatory and immune
(e.g., macrophages, dendritic cells, myeloid suppressor cells,
granulocytes, lymphocytes, etc.), resident and/or recruited cells
that are capable of giving rise to or differentiating into any of
the above-noted non-malignant cells, and any functionally distinct
subtypes of the above-noted cells as known in the art.
[0140] A "subject" can be a mammal in need of treatment, such as a
human or veterinary patient (e.g., rodent, such as a mouse or rat,
a cat, dog, cow, horse, sheep, goat, or other livestock). In some
embodiments, a "subject" may be a clinical patient, a clinical
trial volunteer, an experimental animal, etc. The subject may be
suspected of having or at risk for having a condition characterized
by cell proliferation, be diagnosed with a condition characterized
by cell proliferation, or be a control subject that is confirmed to
not have a condition characterized by cell proliferation, as
described herein. Diagnostic methods for conditions characterized
by cell proliferation and the clinical delineation of such
diagnoses are known to those of ordinary skill in the art.
[0141] The composition can be a liquid solution, suspension,
emulsion, sustained release formulation, or powder, and can be
formulated with a pharmaceutically acceptable carrier. The
composition can be formulated as a suppository, with traditional
binders and carriers such as triglycerides. The term
"pharmaceutically-acceptable carrier" refers to a carrier medium or
vehicle which does not interfere with the effectiveness of the
biological activity of the active ingredients and which is not
toxic to the host or subject.
[0142] Fusion proteins can be delivered along with a
pharmaceutically-acceptable vehicle. In one example, the vehicle
may enhance the stability and/or delivery properties. Thus, the
disclosure also provides for formulation of the fusion protein with
a suitable vehicle, such as an artificial membrane vesicle
(including a liposome, noisome, nanosome and the like),
microparticle or microcapsule, or as a colloidal formulation that
comprises a pharmaceutically acceptable polymer. The use of such
vehicles/polymers may be beneficial in achieving sustained release
of the fusion proteins. Alternatively, or in addition, the fusion
protein formulations can include additives to stabilize the protein
in vivo, such as human serum albumin, or other stabilizers for
protein therapeutics known in the art. Fusion protein formulations
can also include one or more viscosity enhancing agents which act
to prevent backflow of the formulation when it is administered, for
example by injection or via catheter. Such viscosity enhancing
agents include, but are not limited to, biocompatible glycols and
sucrose.
[0143] Pharmaceutical compositions containing one or more fusion
proteins can be formulated as a sterile injectable aqueous or
oleaginous suspension according to methods known in the art and
using suitable one or more dispersing or wetting agents and/or
suspending agents, such as those mentioned above. The sterile
injectable preparation can be a sterile injectable solution or
suspension in a non-toxic parentally acceptable diluent or solvent,
for example, as a solution in 1,3-butanediol. Acceptable vehicles
and solvents that can be employed include, but are not limited to,
water, Ringer's solution, lactated Ringer's solution and isotonic
sodium chloride solution. Other examples include, sterile, fixed
oils, which are conventionally employed as a solvent or suspending
medium, and a variety of bland fixed oils including, for example,
synthetic mono- or diglycerides. Fatty acids such as oleic acid can
also be used in the preparation of injectables.
[0144] In some embodiments, the fusion protein is conjugated to a
water-soluble polymer, e.g., to increase stability or circulating
half-life or reduce immunogenicity. Clinically acceptable,
water-soluble polymers include, but are not limited to,
polyethylene glycol (PEG), polyethylene glycol propionaldehyde,
carboxymethylcellulose, dextran, polyvinyl alcohol (PVA),
polyvinylpyrrolidone (PVP), polypropylene glycol homopolymers
(PPG), polyoxyethylated polyols (POG) (e.g., glycerol) and other
polyoxyethylated polyols, polyoxyethylated sorbitol, or
polyoxyethylated glucose, and other carbohydrate polymers. Methods
for conjugating polypeptides to water-soluble polymers such as PEG
are described, e.g., in U.S. patent Pub. No. 20050106148 and
references cited therein. In one example the polymer is a
pH-sensitive polymers designed to enhance the release of drugs from
the acidic endosomal compartment to the cytoplasm (see for example,
Henry et al., Biomacromolecules 7(8):2407-14, 2006).
[0145] Typically vaccines are prepared in an injectable form,
either as a liquid solution or as a suspension. Solid forms
suitable for injection may also be prepared as emulsions, or with
the polypeptides encapsulated in liposomes. The cells are injected
in any suitable carrier known in the art. Suitable carriers
typically comprise large macromolecules that are slowly
metabolized, such as proteins, polysaccharides, polylactic acids,
polyglycolic acids, polymeric amino acids, amino acid copolymers,
lipid aggregates, and inactive virus particles. Such carriers are
well known to those skilled in the art. These carriers may also
function as adjuvants.
[0146] Adjuvants are immunostimulating agents that enhance vaccine
effectiveness. Effective adjuvants include, but are not limited to,
aluminum salts such as aluminum hydroxide and aluminum phosphate,
muramyl peptides, bacterial cell wall components, saponin
adjuvants, and other substances that act as immunostimulating
agents to enhance the effectiveness of the composition.
[0147] Vaccines are administered in a manner compatible with the
dose formulation. By an effective amount is meant a single dose, or
a vaccine administered in a multiple dose schedule, that is
effective for the treatment or prevention of a disease or disorder.
Preferably, the dose is effective to inhibit the growth of a
neoplasm. The dose administered will vary, depending on the subject
to be treated, the subject's health and physical condition, the
capacity of the subject's immune system to produce antibodies, the
degree of protection desired, and other relevant factors. Precise
amounts of the active ingredient required will depend on the
judgement of the practitioner.
[0148] The pharmaceutical compositions described herein include one
or more fusion proteins in an amount effective to achieve the
intended purpose. Typically, compositions including a fusion
protein containing a pro-apoptotic Bcl-2 family member are
administered to a patient already suffering from a disease,
disorder or condition characterized by cell proliferation, or at
risk for such a disease, disorder or condition, in an amount
sufficient to cure or at least partially arrest a symptom
associated with cell proliferation or reduce cell growth.
[0149] The skilled person will therefore recognize that the dosage
to be administered is not subject to defined limits. Prior to
administration for therapeutic purposes, the dosage of the fusion
protein may need to be modified or adapted for the particular
purpose, for example the concentration of fusion protein needed for
whole body administration may differ from that used for local
administration. Similarly, the toxicity of the therapeutic may
change depending upon the mode of administration and overall
composition being used (e.g., buffer, diluent, additional
chemotherapeutic, etc.).
[0150] An "effective amount" of a pharmaceutical composition
according to the invention includes a therapeutically effective
amount or a prophylactically effective amount. A "therapeutically
effective amount" refers to an amount of the fusion protein
effective, at dosages and for periods of time necessary, that
ameliorates the symptoms of the disease, disorder or condition to
be treated. A therapeutically effective amount of a compound may
vary according to factors such as the disease state, age, sex, and
weight of the subject, and the ability of the compound to elicit a
desired response in the subject. Dosage regimens may be adjusted to
provide the optimum therapeutic response. A therapeutically
effective amount is also one in which any toxic or detrimental
effects of the fusion protein are outweighed by the therapeutically
beneficial effects. Determination of a therapeutically effective
dose of a compound is well within the capability of those skilled
in the art. For example, the therapeutically effective dose can be
estimated initially either in cell culture assays, or in animal
models, such as those described herein. A "prophylactically
effective amount" refers to to an amount of the fusion protein
effective, at dosages and for periods of time necessary, that
achieves the desired prophylactic result, such as delay in onset of
symptoms of a neurological disorder or continued remission of a
cancer. Animal models can also be used to determine the appropriate
concentration range and route of administration. Such information
can then be used to determine useful doses and routes for
administration in other animals, including humans, using standard
methods known in those of ordinary skill in the art.
[0151] Concentration of the fusion protein in the final formulation
can be at least 0.1 mg/mL, such as at least 1 ng/mL or at least 1
ug/mL or at least 1 mg/mL. For example, the concentration in the
final formulation can be between about 0.01 ug/mL and about 1,000
ug/mL. In one example, the concentration in the final formulation
is between about 0.01 mg/mL and about 100 mg/mL.
[0152] In some embodiments, a fusion protein including an
anti-apoptotic Bcl-2 family protein, or fragment thereof, is
administered at concentrations ranging from about 10 ng/mL to about
10,000 ng/mL, or any value therebetween, such as about 25 ng/mL, 50
ng/mL, 75 ng/mL, 100 ng/mL, 150 ng/mL, 200 ng/mL, 250 ng/mL, 300
ng/mL, 350 ng/mL, 400 ng/mL, 450 ng/mL, 500 ng/mL, 550 ng/mL, 600
ng/mL, 650 ng/mL, 700 ng/mL, 750 ng/mL, 800 ng/mL, 850 ng/mL, 900
ng/mL, 950 ng/mL, 1000 ng/mL, 1500 ng/mL, 2000 ng/mL, 2500 ng/mL,
3000 ng/mL, 3500 ng/mL, 4000 ng/mL, 4500 ng/mL, 5000 ng/mL, 5500
ng/mL, 6000 ng/mL, 6500 ng/mL, 7000 ng/mL, 7500 ng/mL, 8000 ng/mL,
8500 ng/mL, 9000 ng/mL, 9500 ng/mL, or 10000 ng/mL.
[0153] In some embodiments, a fusion protein including an
pro-apoptotic Bcl-2 family protein, or fragment thereof, is
administered at concentrations ranging from about 0.1 ng/mL to
about 10,000 ng/mL
[0154] However, it will be understood that the actual amount of the
compound(s) to be administered will be determined by a physician,
in the light of the relevant circumstances, including the condition
to be treated, the chosen route of administration, the actual
compound administered, the age, weight, and response of the
individual patient, and the severity of the patient's symptoms. The
above dosage range is given by way of example only and is not
intended to limit the scope in any way. In some instances dosage
levels below the lower limit of the aforesaid range may be more
than adequate, while in other cases still larger doses may be
employed without causing harmful side effects, for example, by
first dividing the larger dose into several smaller doses for
administration throughout the day.
[0155] One of ordinary skill in the art will appreciate that the
dosage will depend, among other things, upon the type of fusion
protein being used and the type of disorder or condition being
treated.
[0156] In general, the fusion proteins according to the present
disclosure contain substantially human sequences and are therefore
less antigenic than, for example, immunotoxins or other molecules
that contain non-human sequences. In some embodiments, the fusion
proteins according to the present disclosure contain at least 80%,
for example, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% human
sequences. In some embodiments, the fusion proteins according to
the present disclosure can be administered at substantially lower
doses than for example, immunotoxins, or native IL-4R binding
protein, such as IL-4 or IL-13.
[0157] In some embodiments, the fusion proteins may elicit some
level of antibody response when administered to a subject, which in
some cases may lead to undesirable side effects. Therefore, if
necessary, the antigenicity of the fusion proteins can be assessed
as known in the art and/or described herein. For example, in vivo
toxic effects of the fusion proteins can be evaluated by measuring
their effect on animal body weight during treatment and by
performing hematological profiles and liver enzyme analysis after
the animal has been killed. The general toxicity of the fusion
proteins can be tested according to methods known in the art. For
example, the overall systemic toxicity of the fusion proteins can
be tested by determining the dose that kills 100% of mice (i.e.
LDioo) or kills 50% of mice (i.e. LD50) following a single
intravenous injection. Doses that are at least about 2, 5, or
10-fold less than the LDioo or LD50 can be selected for
administration into other mammals, such as a human.
[0158] The kinetics and magnitude of the antibody response to the
fusion proteins described herein can be determined, for example, in
immunocompetent mice and can be used to facilitate the development
of a dosing regimen that can be used in an immunocompetent
human.
[0159] Immunocompetent mice such as the strain C57-BL6 are
administered intravenous doses of fusion protein. The mice are
killed at varying intervals (e.g. following single dose, following
multiple doses) and serum obtained. An ELISA-based assay can be
used to detect the presence of anti-fusion protein antibodies.
[0160] Serum samples from mice can be assessed for the presence of
anti-fusion protein antibodies as known in the art. As another
example, epitope mapping can also be used to determine antigenicity
of proteins as described in Stickler, et al., J. Immunotherapy,
23:654-660, 2000. Briefly, immune cells known as dendritic cells
and CD4+ T cells are isolated from the blood of community donors
who have not been exposed to the protein of interest. Small
synthetic peptides spanning the length of the protein are then
added to the cells in culture. Proliferation in response to the
presence of a particular peptide suggests that a T cell epitope is
encompassed in the sequence. This peptide sequence can subsequently
be deleted or modified in the fusion protein thereby reducing its
antigenicity.
[0161] Therapeutic efficacy and toxicity can also be determined by
standard pharmaceutical procedures such as, for example, by
determination of the median effective dose, or ED50 (i.e. the dose
therapeutically effective in 50% of the population) and the median
lethal dose, or LD50 (i.e. the dose lethal to 50% of the
population). The dose ratio between therapeutic and toxic effects
is known as the "therapeutic index," which can be expressed as the
ratio, LD50/ED50. The data obtained from cell culture assays and
animal studies can be used to formulate a range of dosage for human
or animal use. The dosage contained in such compositions is usually
within a range of concentrations that include the ED50 and
demonstrate little or no toxicity. The dosage varies within this
range depending upon the dosage form employed, sensitivity of the
subject, and the route of administration and the like.
[0162] Administration of the fusion proteins can be
intralesionally, for instance by direct injection directly into the
apoptotic tissue site; into a site that requires cell growth; into
a site where a cell, tissue or organ is at risk of cell death; or
into a site of hyperproliferati on or into a tumor. Alternatively,
the fusion protein can be administered systemically. For methods of
combination therapy comprising administration of a fusion protein
in combination with a chemotherapeutic agent, the order in which
the compositions are administered is interchangeable. Concomitant
administration is also envisioned.
[0163] Typically in the treatment of cancer, fusion proteins are
administered systemically to patients, for example, by bolus
injection or continuous infusion into a patient's bloodstream.
Alternatively, the fusion proteins may be administered locally, at
the site of a tumor (intratumorally). When a fusion protein is
administered intratumorally, the administration can be via any
route, e.g., locally, regionally, focally, systemic, convection
enhanced delivery or combinations thereof.
[0164] When used in conjunction with one or more known
chemotherapeutic agents, the compounds can be administered prior
to, or after, administration of the chemotherapeutic agents, or
they can be administered concomitantly. The one or more
chemotherapeutics may be administered systemically, for example, by
bolus injection or continuous infusion, or they may be administered
orally.
[0165] For administration to an animal, the pharmaceutical
compositions can be formulated for administration by a variety of
routes. For example, the compositions can be formulated for
topical, rectal or parenteral administration or for administration
by inhalation or spray. The term parenteral as used herein includes
subcutaneous injections, intravenous, intramuscular, intrathecal,
intrasternal injection or infusion techniques. Direct injection or
infusion into a tumor is also contemplated. Convection enhanced
delivery can also be used to administer the fusion protein.
[0166] In one example, the fusion protein can be injected into a
subject having cancer, using an administration approach similar to
the multiple injection approach of brachytherapy. For example,
multiple aliquots of the purified fusion protein in the form of a
pharmaceutical composition or formulation and in the appropriate
dosage units, may be injected using a needle. Alternative methods
of administration of the fusion proteins will be evident to one of
ordinary skill in the art. Such methods include, for example, the
use of catheters, or implantable pumps to provide continuous
infusion of the fusion protein to the subject in need of
therapy.
[0167] As is known in the art, software planning programs can be
used in combination with brachytherapy treatment and ultrasound,
for example, for placement of catheters for infusing fusion
proteins to treat, for example, brain tumors or other localized
tumors. For example, the positioning and placement of the needle
can generally be achieved under ultrasound guidance. The total
volume, and therefore the number of injections and deposits
administered to a patient, can be adjusted, for example, according
to the volume or area of the organ to be treated. An example of a
suitable software planning program is the brachytherapy treatment
planning program Variseed 7.1 (Varian Medical Systems, Palo Alto,
Calif.) or iPlan (BrainLab, Munich, Germany) for convection
enhanced delivery to the brain. Such approaches have been
successfully implemented in the treatment of prostate cancer and
brain cancer among among others.
[0168] Fusion proteins can be used in inhibiting cell survival or
inhibiting cell proliferation in the central nervous system (CNS).
When the site of delivery is the brain, the fusion protein must be
capable of being delivered to the brain. The blood-brain barrier
limits the uptake of many therapeutic agents into the brain and
spinal cord from the general circulation. Molecules which cross the
blood-brain barrier use two main mechanisms: free diffusion and
facilitated transport. Because of the presence of the blood-brain
barrier, attaining beneficial concentrations of a given fusion
protein in the CNS may require the use of specific drug delivery
strategies. Delivery of fusion proteins to the CNS can be achieved
by several methods.
[0169] One method relies on neurosurgical techniques. For instance,
fusion proteins can be delivered by direct physical introduction
into the CNS, such as intraventricular, intralesional, or
intrathecal injection. Intraventricular injection can be
facilitated by an intraventricular catheter, for example, attached
to a reservoir, such as an Ommaya reservoir. Methods of
introduction are also provided by rechargeable or biodegradable
devices. Another approach is the disruption of the blood-brain
barrier by substances which increase the permeability of the
blood-brain barrier. Examples include intra-arterial infusion of
poorly diffusible agents such as mannitol, pharmaceuticals which
increase cerebrovascular permeability such as etoposide, or
vasoactive agents, such as leukotrienes or by convention enhanced
delivery by catheter (CED). Further, it may be desirable to
administer the compositions locally to the area in need of
treatment; this can be achieved, for example, by local infusion
during surgery, by injection, by means of a catheter, or by means
of an implant, the implant being of a porous, non-porous, or
gelatinous material, including membranes, such as silastic
membranes, or fibers. A suitable membrane is Gliadel.RTM. (Eisai
Inc.).
[0170] Non-viral approaches can also be employed for the
introduction of a therapeutic to a cell requiring modulation of
cell death (e.g., a cell of a patient). For example, a nucleic acid
molecule can be introduced into a cell by administering the nucleic
acid molecule in the presence of lipofection (Feigner et al., Proc.
Natl. Acad. Sci. U.S.A. 84:7413, 1987; Ono et al., Neuroscience
Letters 17:259, 1990; Brigham et al., Am. J. Med. Sci. 298:278,
1989; Staubinger et al., Methods in Enzymology 101:512, 1983),
asialoorosomucoid-polylysine conjugation (Wu et al., Journal of
Biological Chemistry 263:14621, 1988; Wu et al., Journal of
Biological Chemistry 264:16985, 1989), or by micro-injection under
surgical conditions (Wolff et al., Science 247:1465, 1990).
Preferably the nucleic acids are administered in combination with a
liposome and protamine.
[0171] Gene transfer can also be achieved using non-viral means
involving transfection in vitro. Such methods include the use of
calcium phosphate, DEAE dextran, electroporation, and protoplast
fusion. Liposomes can also be potentially beneficial for delivery
of DNA into a cell. Transplantation of a fusion protein into the
affected tissues of a patient can also be accomplished by
transferring a normal nucleic acid into a cultivatable cell type ex
vivo (e.g., an autologous or heterologous primary cell or progeny
thereof), after which the cell (or its descendants) are injected
into a targeted tissue.
[0172] cDNA expression for use in polynucleotide therapy methods
can be directed from any suitable promoter (e.g., the human
cytomegalovirus (CMV), simian virus 40 (SV40), or metallothionein
promoters), and regulated by any appropriate mammalian regulatory
element. For example, if desired, enhancers known to preferentially
direct gene expression in specific cell types can be used to direct
the expression of a nucleic acid. The enhancers used can include,
without limitation, those that are characterized as tissue- or
cell-specific enhancers. Alternatively, if a genomic clone is used
as a therapeutic construct, regulation can be mediated by the
cognate regulatory sequences or, if desired, by regulatory
sequences derived from a heterologous source, including any of the
promoters or regulatory elements described above.
[0173] The present invention will be further illustrated in the
following examples.
EXAMPLES
Example 1
[0174] This example describes making circularly permuted IL-4
proteins.
[0175] The coding sequence of IL-4 is designed to be reorganized
creating a new amino terminus and a new carboxy terminus. The site
of reorganization is selected and coding regions are developed
synthetically or using the native sequence as a template. PCR can
be used to amplify the separate coding regions and the 5' and 3'
ends of the separate fragments are designed to overlap, thus
allowing for the formation of a new coding sequence in which the
newly generated peptide can for example encode a first amino acid
that in the native protein may have been the 40th amino acid.
Specific examples of making circularly permuted ligands are
provided in U.S. Pat. No. 6,011,002.
[0176] The following sequence is used as a reference.
TABLE-US-00025 Name IL-4 Linker Toxin Description cpIL4-
MDTTEKETFCRAAT ASGGPE PE38KDEL Circularly PE VLRQFYSHHEKDT (SEQ ID
permuted RCLGATAQQFHRH NO: 29) human IL-4 KQURFLKRLDRNL fused to a
WGLAGLNSCPVKE Pseudo- ANQSTLENFLERLK monas TIMREKYSKCSS exotoxin
HKCDITLQEIIK (PE38KDEL) TLNSLTEQKTLCTE via a LTVTDIFAASK (SEQ ID
ASGGPE NO: 2). linker
Example 2
[0177] cpIL-4-BAD was prepared using standard techniques and tested
on IL-4Ra-expressing cancer cells in vitro and on IL-4Ra positive
xenograft tumors in an athymic nude mouse model, using cpIL4-PE as
a reference. The results indicated that cpIL-4-BAD was effective at
killing the cancer cells and at regressing the tumors.
[0178] More specifically, cpIL-4-BAD fusion protein was prepared by
transducing BL21(DE3)pLysS bacteria with chimeric plasmid cpIL-4BAD
in a pET 24a expression vector (FIG. 1). The freshly transformed
bacteria were plated on LB with kanamycin. Colonies were picked and
transferred into 1 litre of superbroth enriched with glucose, MgCl2
and kanamycin and the cells were induced with 1 mM IPTG. The growth
of the cells was monitored for 6 hours. IL-4-BAD fusion proteins
were refolded and purified using a HiTrap Column followed by two
rounds of a MonoS column, after which cp1L-4-BAD fractions were
evaluated by SDS-PAGE electrophoresis. This strategy yielded about
0.980 mg/L cpIL-4BAD at pH 6.5, and about 2.930 mg/L cp1L-4BAD at
pH 6.8.
[0179] IL-4Ra positive tumor cells (U 251 cells and Daudi cells)
were plated in quadruplicate in 6-well petri-dishes overnight in
complete medium. 0.1-1000 ng/mL of cpIL-4BAD was added and the
plates were incubated for five days in a CO2 incubator at
37.degree. C. On day 5, the plates were washed with 1.times.PBS and
the cells were detached with trypsin treatment. After trypsin
inactivation, viable cells were counted using the trypan blue
exclusion technique.
[0180] The results indicated that the cp1L-4BAD fusion protein
killed U 251 cells in a concentration dependent manner in vitro,
with an IC50 value of about 0.6 ng/mL (FIG. 2). 100.times. excess
of IL-4 blocked the ability of cp1L-4BAD to kill the U 251 cells,
demonstrating that the cpIL-4BAD activity was specific (FIG. 3).
Also, the IC50 value rose from about 0.3 ng/mL to >1000 ng/mL in
5-day cell viability assays.
[0181] The cpIL-4BAD fusion protein killed Daudi cells in a
concentration-dependant manner in vitro, with an IC50 value of
about 0.1 ng/mL (FIG. 4). 100.times. excess of IL-4 also blocked
the ability of cpIL-4BAD to kill the Daudi cells, demonstrating
that the cpIL-4BAD activity was specific (FIG. 5). The IC50 value
rose from about 0.3 ng/mL to >1000 ng/mL in 5-day cell viability
assays.
[0182] The cp1L-4BAD fusion protein was also found to decrease the
colony numbers of IL-4Ra positive tumor cells in a colony formation
assay. More specifcally, 5000 U 251 cells were plated in 10 cm
culture plates (6 plates in total), cp1L-4BAD was added and the
cells were incubated for 10 days. Colonies were stained with
Crystal Blue and counted. The results indicated that cp1L-4BAD
decreased U 251 colony numbers in a concentration dependent manner
in vitro, with an IC50 value of about 5 ng/mL (FIG. 6).
[0183] The effectiveness of the cp1L-4BAD fusion protein was
assessed in athymic mice after the development of subcutaneous
glioma tumors with U 251 tumor cells. More specifically, cpIL-4BAD
was injected intratumourally (IT) at 100 .mu.g/kg (6 injections)
and intraperitoneally (IP) 100 .mu.g/kg (6 injections). 0.2%
HAS/PBS was used as a vehicle control. The assessed end points were
tumor size and survival. The results indicated that IT
administration of cp1L-4BAD regressed the tumor growth
significantly compared to the placebo control-treated animals after
6 injections. IP administration regressed the tumors dramatically
compared to IT treated mice. Tumors in both groups of mice recurred
beyond day 40, when the mice in control groups were euthanized for
ethical reasons, as the tumors were of 2000 mm3 on day 36 (FIG. 7).
cpIL-4BAD-treated mice also survived longer than placebo treated
mice (FIG. 8).
Example 3
[0184] Six additional IL-4Ra positive cell lines were tested for
their sensitivity to the cpIL-4BAD fusion protein and cpIL-4PE
under identical experimental conditions. ICso values were
determined by counting the cells using the trypan blue exclusion
technique (Table 3).
TABLE-US-00026 IC.sub.50 (ng/mL) Cell Line Origin cpIL-4BAD
cpIL-4PE YCUT891 Tongue 11.0 8.0 YCUM862 Oropharynx 1.1 0.6
KCCOR891 Oral Floor 0.15 9.0 KCCL871 Larynx 0.5 1.5 YCUM911
Oropharynx 0.2 4.5 KCCTCM901 Metastasis to the chest fluid 1.0
0.7
Example 4
[0185] IL-4BAD, cpIL-4BAD and cpS4-BAD fusion proteins were
expressed and purified. More specifically, cDNAs of IL-4BAD,
cpIL-4BAD and cpS4-BAD were PCR cloned into BamHI/Xhol sites of a
pGWO7 E. coli. expression vector (FIG. 9). The obtained vectors
were verified by DNA sequencing (FIGS. 10A-D).
[0186] Protein expression was performed in E. coli cells. IL-4BAD,
cpIL-4BAD and cpS4-BAD proteins were expressed in 1 L cultures in
insoluble form, purified under denaturing conditions using IMAC,
followed by "quick dilution" protein refolding. Refolding by "quick
dilution" generated intact proteins free of aggregates, as
determined by non-reducing SDS-PAGE. Final sample size and
concentrations were as follows: IL-4BAD was about 3.5 mL at 0.24
mg/mL, determined by UV280 nm (UV280 nm Abs at 1 mg/ml=1.14);
cpIL-4BAD was about 3.5 mL at 0.23 mg/mL, determined by UV280 nm
(UV280 nm Abs at 1 mg/mL=1.13); and cpS4-BAD was about 3.5 mL at
0.23 mg/mL, determined by UV280 nm (UV280 nm Abs at 1 mg/ml=1.25).
Protein was stored in a storage buffer composition: 500 nM NaCL, 10
mM Na-Phosphate, pH 7.0, 1% glycerol, 1 .mu.M EDTA, 0.01% Tween
20.
[0187] BL21(DE3)pLysS-RARE2 cells were transformed with IL-4BAD,
cp1L-4BAD and cpS4-BAD protein expression constructs, plated on LB
plates supplemented with Amp at 100 .mu.g/mL, and incubated
overnight at 37.degree. C. The next day, colonies from the plate
were scraped and re-suspended in liquid LB medium with 100 .mu.g/mL
of Amp. The cultures were then grown at 37.degree. C., with
aeration, and protein expression was induced by 1 mM IPTG when the
cell culture reached an OD600 of about 0.5. Induction lasted for
about 4 hours at 30.degree. C. The cell pellet was then collected
and stored at -20.degree. C. 10.mu..l_, samples of uninduced and
induced culture were lysed by boiling at 95.degree. C. for 10
minutes in 50 uL of reducing protein loading buffer and run on an
SDS-PAGE gel. Cells from a 1 mL sample collected at 4 hours
post-induction were lysed in hypotonic buffer, sonicated and
centrifuged for 10 minutes at 13,000 rpm. Aliquots from the soluble
and insoluble fraction were boiled in reducing protein loading
buffer and analyzed on an SDS-PAGE gel. Estimated expression levels
observed for IL-4BAD, cp1L-4BAD proteins was more than 50 mg/L of
crude material. Estimated expression levels observed for cpS4-BAD
was more than 50 mg/L. IL-4BAD was found to be almost completely
insoluble, with some possible soluble form (less than 5%). cpS4-BAD
were mainly in the insoluble fraction.
[0188] The cell pellets from the induced cultures were lysed at
room temperature and the inclusion bodies fraction was collected
and washed with PBS-T. The insoluble material was solubilized in 8M
Urea and bound to 3 mL Ni-charged resin. The resin was washed with
15 CV of wash buffer and the bound protein was eluted in 8 CV
elutions of step gradient of imidazole in wash buffer. 7.5 .mu.L
from each fraction was analyzed on a SDS-PAGE gel. The fractions
with the highest amount of IL-4BAD (about 6 mg) and cp1L-4BAD
(about 8 mg) were combined and refolded. The remaining fractions
were stored at -20.degree. C.
[0189] The IL-4BAD and cp1L-4BAD fractions were combined, reduced
by the addition of 1 mM DTT and subjected to a slow step-wise
dialysis against storage buffer (150 mM NaCl, 10 mM HEPES, pH 7.4,
0.01% Tween 20) supplemented with a decreasing concentration of
urea at each dialysis buffer change. The protein concentration was
measured after each dialysis step by UV Spectroscopy: IL-4BAD was
about 0.8 mg; and cp1L-4BAD was about 0.45 mg. The samples were
then run on an SDS-PAGE gel.
[0190] 25 .mu.L of each protein (-0.6 mg/mL, 200 mM Imidazole
fraction) was diluted in 1 mL of the following buffers: 20 mM
HEPES, pH 7.4, 1% glycerol, 10 .mu.M EDTA, 0.01% Tween (Buffer 1);
10 mM Na-Phosphate, pH 7.0, 1% Glycerol, 10 .mu.M EDTA, 0.01% Tween
(Buffer 2); and PBS, pH 7.2 (Buffer 3). The samples were stored
overnight at room temperature. The next day, the samples were spun
for 10 minutes at 13,000 rpm and the presence of the pellet in each
sample was observed and recorded in Table 2: (+++) indicates an
abundant pellet; (-) indicates no visible pellet.
TABLE-US-00027 TABLE 2 IL-4BAD and cplL-4BAD pellets in Buffers 1,
2 and 3. Pellet after Pellet after 114-BAD refolding cpIL4-BAD,
refolding 10 mM Buffer 1 NaCI, 100 mM Sample 1 (+++) Sample 13
(+++) DTT NaCI, 500 mM Sample 2 (+++) Sample 14 (++) NaCI, 20 mM
Sample 3 (++) Sample 15 (+++) Buffer 2 NaCI, 100 mM Sample 4 (-)
Sample 16 (+++) NaCI, 500 mM Sample 5 (+) Sample 17 (++) NaCI, 20
mM Sample 6 (+++) Sample 18 (+++) Buffer 3 Sample 25 (++) Sample 27
(+++) w/o Buffer 1 NaCI, 100 mM Sample 7 (+) Sample 19 (++)
reducing NaCI, 500 mM Sample 8 (+) Sample 20 (++) agents NaCI, 20
mM Sample 9 (-) Sample 21 (++) Buffer 1 NaCI, 100 mM Sample 10 (-)
Sample 22 (++) NaCI, 500 mM Sample 11 (+) Sample 23 (+) NaCI, 20 mM
Sample 12 (+) Sample 24 (+++) Buffer 3 Sample 26 (+) Sample 28
(-)
[0191] The samples were also analyzed on non-reducing SDS-PAGE gel.
Refolded samples were concentrated to 100 .mu.L using Amicon 10 kDa
MWCO, spun down, and a 7.5 .mu.L aliquot of each sample was run on
an SDS-PAGE gel.
[0192] The purification process was repeated using quick dilution
folding. 4 ml of 200 mM imidazole fractions containing IL-4BAD,
cp1L-4BAD or cpS4-BAD was quickly diluted into 200 mL of refolding
buffer (500 mM NaCl, 10 mM Na-Phosphate, pH 7.0 or 6.0 or 7.8, 1%
Glycerol, 10[1.M EDTA, 0.01% Tween), incubated overnight at room
temperature, spun down for 20 minutes at 4,000 rpm at 4.degree. C.,
concentrated to 3 mL using an Amicon 10 kDa MWCO, and buffer
exchanged into storage buffer (500 mM NaCl, 10 mM Na-Phosphate, pH
7.0 or 6.0 or 7.8, 1% Glycerol, 1 .mu.M EDTA, 0.01% Tween) using a
DG-10 column. Final sample concentrations were as follows: 3.5 mL
of IL-4B AD at about 0.24 mg/mL; 3.5 mL of cp1L-4BAD at about 0.23
mg/mL. The final samples were run on an SDS-PAGE gel.
[0193] The final concentration of cpS4-BAD was about 3.5 mL at
about 0.23 mg/mL. The final sample was run on an SDS-PAGE gel.
Example 5
[0194] A pKFR4-BAD-H6 fusion protein (FIGS. 11A-B) was prepared as
follows. cDNA of pKFR4-BAD-H6 was PCR cloned into the Ndel/Xhol
sites of a pET-21a(+) vector. The vector was then transformed into
HMS174(DE3) cells and induced with 0.1 mM IPTG for 3 hours. Samples
were run on an SDS-PAGE gel before and after induction. The cells
were pelleted and lysed by ultrasonication in a buffer containing
20 mM Tris-HCl, 300 mM NaCl, 20 mM Imidazole, pH 8.0, and samples
were run on an SDS-PAGE gel.
[0195] Inclusion bodies were dissolved in a dissolving buffer of 20
mM Tris-HCl, 300 mM NaCl, 20 mM Imidazole, 20 mM beta-ME, 7 M
GuaHCl, pH 8.0. The supernatant was then purified by Ni2I affinity
chromatography. pKFR4-BAD-H6 was eluted by 20 mM Tris-HCl, 300 mM
NaCl, 300 mM Imidazole, 8 M Urea, pH 8.0 under reducing and
non-reducing conditions. Samples were taken throughout the
purification process.
[0196] After purification, pKFR4-BAD-H6 was dialyzed in dialysis
buffer: 0.1% TFA, 30% acetonitrile under reducing conditions and
non-reducing conditions, yielding a concentration of about 2.67
mg/mL.
Example 6
[0197] To evaluate the potency of fusion proteins on
IL-4R-expressing cell lines, EH suspension cells that express Type
I IL-4R, were cultured in RPMI1640 (from Gibco) containing 10% FBS
(from Life Technologies), 2 mM L-glutamine (from Gibco) and 10 mM
HEPES (from Gibco). cpS4-BAD was added to the cell suspension. The
cell suspension was poured into a 96-well Isoplate in an amount of
about 1.times.104 cells/well. The cell suspensions were incubated
at 37.degree. C. in a 5% CO2 incubator for 48 hours. Before the end
of the 48-hour incubation, 100 .mu.Ci/mL of [3H]-thymidine in
complete medium was prepared and 10 .mu.L was added into each well
of the culture. After 6 hours of incubation with [3I-1]-thymidine,
50 .mu.L of 50% trichloroacetic acid was slowly added into each
well and incubated at 4.degree. C. for 2 hours. The plates were
then washed five times with dH2O, and air-dried. 100 .mu.L of
scintillation liquid was added to each well and the plates were
left at room temperature overnight. The next day, the radioactivity
was read in a MicroBeta Trilux. Data was collected and standardized
using the reading from the control well (cell only). The background
reading (blank) was subtracted from the readings of all the wells,
and the inhibition (% inhibition) was calculated. The IC50 of
cpS4-BAD was about 126.3 ng/mL, which was about 3 times more potent
than MDNA55 (cpIL4-PE; 362.4 ng/mL) which was used as a
reference.
[0198] All citations are hereby incorporated by reference.
[0199] The present invention has been described with regard to one
or more embodiments. However, it will be apparent to persons
skilled in the art that a number of variations and modifications
can be made without departing from the scope of the invention as
defined in the claims.
Sequence CWU 1
1
471130PRTArtificial SequenceIL-4 including an additional methionine
at the N-terminus 1Met His Lys Cys Asp Ile Thr Leu Gln Glu Ile Ile
Lys Thr Leu Asn1 5 10 15Ser Leu Thr Glu Gln Lys Thr Leu Cys Thr Glu
Leu Thr Val Thr Asp 20 25 30Ile Phe Ala Ala Ser Lys Asn Thr Thr Glu
Lys Glu Thr Phe Cys Arg 35 40 45Ala Ala Thr Val Leu Arg Gln Phe Tyr
Ser His His Glu Lys Asp Thr 50 55 60Arg Cys Leu Gly Ala Thr Ala Gln
Gln Phe His Arg His Lys Gln Leu65 70 75 80Ile Arg Phe Leu Lys Arg
Leu Asp Arg Asn Leu Trp Gly Leu Ala Gly 85 90 95Leu Asn Ser Cys Pro
Val Lys Glu Ala Asn Gln Ser Thr Leu Glu Asn 100 105 110Phe Leu Glu
Arg Leu Lys Thr Ile Met Arg Glu Lys Tyr Ser Lys Cys 115 120 125Ser
Ser 1302130PRTArtificial SequenceIL-4 including an additional
methionine at the N-terminus 2Met His Lys Cys Asp Ile Thr Leu Gln
Glu Ile Ile Lys Thr Leu Asn1 5 10 15Ser Leu Thr Glu Gln Lys Thr Leu
Cys Thr Glu Leu Thr Val Thr Asp 20 25 30Ile Phe Ala Ala Ser Lys Asp
Thr Thr Glu Lys Glu Thr Phe Cys Arg 35 40 45Ala Ala Thr Val Leu Arg
Gln Phe Tyr Ser His His Glu Lys Asp Thr 50 55 60Arg Cys Leu Gly Ala
Thr Ala Gln Gln Phe His Arg His Lys Gln Leu65 70 75 80Ile Arg Phe
Leu Lys Arg Leu Asp Arg Asn Leu Trp Gly Leu Ala Gly 85 90 95Leu Asn
Ser Cys Pro Val Lys Glu Ala Asn Gln Ser Thr Leu Glu Asn 100 105
110Phe Leu Glu Arg Leu Lys Thr Ile Met Arg Glu Lys Tyr Ser Lys Cys
115 120 125Ser Ser 1303134PRTArtificial Sequencecircularly permuted
IL-4 3Met Asp Thr Thr Glu Lys Glu Thr Phe Cys Arg Ala Ala Thr Val
Leu1 5 10 15Arg Gln Phe Tyr Ser His His Glu Lys Asp Thr Arg Cys Leu
Gly Ala 20 25 30Thr Ala Gln Gln Phe His Arg His Lys Gln Leu Ile Arg
Phe Leu Lys 35 40 45Arg Leu Asp Arg Asn Leu Trp Gly Leu Ala Gly Leu
Asn Ser Cys Pro 50 55 60Val Lys Glu Ala Asn Gln Ser Thr Leu Glu Asn
Phe Leu Glu Arg Leu65 70 75 80Lys Thr Ile Met Arg Glu Lys Tyr Ser
Lys Cys Ser Ser Gly Gly Asn 85 90 95Gly Gly His Lys Cys Asp Ile Thr
Leu Gln Glu Ile Ile Lys Thr Leu 100 105 110Asn Ser Leu Thr Glu Gln
Lys Thr Leu Cys Thr Glu Leu Thr Val Thr 115 120 125Asp Ile Phe Ala
Ala Ser 1304134PRTArtificial Sequencecircularly permuted "RGA" IL-4
variant 4Met Asp Thr Thr Glu Lys Glu Thr Phe Cys Arg Ala Ala Thr
Val Leu1 5 10 15Arg Gln Phe Tyr Ser His His Glu Lys Asp Thr Arg Cys
Leu Gly Ala 20 25 30Thr Ala Gln Gln Phe His Arg His Lys Gln Leu Ile
Arg Phe Leu Lys 35 40 45Arg Leu Asp Arg Asn Leu Trp Gly Leu Ala Gly
Leu Asn Ser Cys Pro 50 55 60Val Lys Glu Ala Asn Gln Ser Thr Leu Glu
Asn Phe Leu Glu Arg Leu65 70 75 80Arg Val Ile Met Gln Ser Lys Trp
Phe Lys Cys Gly Ala Gly Gly Asn 85 90 95Gly Gly His Lys Cys Asp Ile
Thr Leu Gln Glu Ile Ile Lys Thr Leu 100 105 110Asn Ser Leu Thr Glu
Gln Lys Thr Leu Cys Thr Glu Leu Thr Val Thr 115 120 125Asp Ile Phe
Ala Ala Ser 1305134PRTArtificial Sequencecircularly permuted "KFR"
IL-4 variant 5Met Asp Thr Thr Glu Lys Glu Thr Phe Cys Arg Ala Ala
Thr Val Leu1 5 10 15Arg Gln Phe Tyr Ser His His Glu Lys Asp Thr Arg
Cys Leu Gly Ala 20 25 30Thr Ala Gln Gln Phe His Arg His Lys Gln Leu
Ile Arg Phe Leu Lys 35 40 45Arg Leu Asp Arg Asn Leu Trp Gly Leu Ala
Gly Leu Asn Ser Cys Pro 50 55 60Val Lys Glu Ala Asn Gln Ser Thr Leu
Glu Asn Phe Leu Glu Arg Leu65 70 75 80Lys Thr Ile Met Lys Glu Lys
Phe Arg Lys Cys Ser Ser Gly Gly Asn 85 90 95Gly Gly His Lys Cys Asp
Ile Thr Leu Gln Glu Ile Ile Lys Thr Leu 100 105 110Asn Ser Leu Thr
Glu Gln Lys Thr Leu Cys Thr Glu Leu Thr Val Thr 115 120 125Asp Ile
Phe Ala Ala Ser 1306133PRTArtificial Sequencecircularly permuted
"KF" IL-4 variant 6Met Asp Thr Thr Glu Lys Glu Thr Phe Cys Arg Ala
Ala Thr Val Leu1 5 10 15Arg Gln Phe Tyr Ser His His Glu Lys Asp Thr
Arg Cys Leu Gly Ala 20 25 30Thr Ala Gln Gln Phe His Arg His Lys Gln
Leu Ile Arg Phe Leu Lys 35 40 45Arg Leu Asp Arg Asn Leu Trp Gly Leu
Ala Gly Leu Asn Ser Cys Pro 50 55 60Val Lys Glu Ala Asn Gln Ser Thr
Leu Glu Asn Phe Leu Glu Arg Leu65 70 75 80Lys Thr Ile Met Lys Glu
Lys Phe Lys Cys Ser Ser Gly Gly Asn Gly 85 90 95Gly His Lys Cys Asp
Ile Thr Leu Gln Glu Ile Ile Lys Thr Leu Asn 100 105 110Ser Leu Thr
Glu Gln Lys Thr Leu Cys Thr Glu Leu Thr Val Thr Asp 115 120 125Ile
Phe Ala Ala Ser 1307114PRTArtificial SequenceIL-13 including an
additional methionine at the N-terminus 7Met Pro Gly Pro Val Pro
Pro Ser Thr Ala Leu Arg Glu Leu Ile Glu1 5 10 15Glu Leu Val Asn Ile
Thr Gln Asn Gln Lys Ala Pro Leu Cys Asn Gly 20 25 30Ser Met Val Trp
Ser Ile Asn Leu Thr Ala Gly Met Tyr Cys Ala Ala 35 40 45Leu Glu Ser
Leu Ile Asn Val Ser Gly Cys Ser Ala Ile Glu Lys Thr 50 55 60Gln Arg
Met Leu Ser Gly Phe Cys Pro His Lys Val Ser Ala Gly Gln65 70 75
80Phe Ser Ser Leu His Val Arg Asp Thr Lys Ile Glu Val Ala Gln Phe
85 90 95Val Lys Asp Leu Leu Leu His Leu Lys Lys Leu Phe Arg Glu Gly
Gln 100 105 110Phe Asn8114PRTArtificial Sequence"A11" variant IL-13
8Met Pro Gly Pro Val Pro Pro Ser Thr Ala Val Arg Glu Leu Ile Glu1 5
10 15Glu Leu Ile Asn Ile Thr Gln Asn Gln Lys Ala Pro Leu Cys Asn
Gly 20 25 30Ser Met Val Trp Ser Ile Asn Arg Thr Ala Gly Met Tyr Cys
Ala Ala 35 40 45Leu Glu Ser Leu Ile Asn Val Ser Gly Cys Ser Ala Ile
Glu Lys Thr 50 55 60Gln Arg Met Leu Ser Gly Phe Cys Pro His Lys Val
Ser Ala Gly Gln65 70 75 80Phe Ser Ser Leu His Val Arg Ser Ser Lys
Ile Glu Val Ala Gln Phe 85 90 95Val Lys Asp Leu Leu Phe His Leu Arg
Thr Leu Phe Arg Glu Gly Gln 100 105 110Phe Asn9114PRTArtificial
Sequence"DN" variant IL-13 9Met Pro Gly Pro Val Pro Pro Ser Thr Ala
Val Arg Ala Leu Ile Glu1 5 10 15Glu Leu Ile Asn Ile Thr Gln Asn Gln
Lys Ala Pro Leu Cys Asn Gly 20 25 30Ser Met Val Trp Ser Ile Asn Leu
Thr Ala Gly Met Tyr Cys Ala Ala 35 40 45Leu Glu Ser Leu Ile Asn Val
Ser Gly Cys Ser Ala Ile Glu Lys Thr 50 55 60Gln Asp Met Leu Ser Gly
Phe Cys Pro His Lys Val Ser Ala Gly Gln65 70 75 80Phe Ser Ser Leu
His Val Arg Ser Ser Lys Ile Glu Val Ala Gln Phe 85 90 95Val Lys Asp
Leu Leu Phe His Leu Arg Thr Leu Phe Arg Glu Gly Gln 100 105 110Phe
Asn10117PRTArtificial Sequencecircularly permuted IL-13 10Met Tyr
Cys Ala Ala Leu Glu Ser Leu Ile Asn Val Ser Gly Cys Ser1 5 10 15Ala
Ile Glu Lys Thr Gln Arg Met Leu Ser Gly Phe Cys Pro His Lys 20 25
30Val Ser Ala Gly Gln Phe Ser Ser Leu His Val Arg Asp Thr Lys Ile
35 40 45Glu Val Ala Gln Phe Val Lys Asp Leu Leu Leu His Leu Lys Lys
Leu 50 55 60Phe Arg Glu Gly Gln Phe Asn Gly Gly Ser Gly Pro Gly Pro
Val Pro65 70 75 80Pro Ser Thr Ala Leu Arg Glu Leu Ile Glu Glu Leu
Val Asn Ile Thr 85 90 95Gln Asn Gln Lys Ala Pro Leu Cys Asn Gly Ser
Met Val Trp Ser Ile 100 105 110Asn Leu Thr Ala Gly
11511118PRTArtificial Sequencecircularly permuted IL-13 11Met Tyr
Cys Ala Ala Leu Glu Ser Leu Ile Asn Val Ser Gly Cys Ser1 5 10 15Ala
Ile Glu Lys Thr Gln Arg Met Leu Ser Gly Phe Cys Pro His Lys 20 25
30Val Ser Ala Gly Gln Phe Ser Ser Leu His Val Arg Asp Thr Lys Ile
35 40 45Glu Val Ala Gln Phe Val Lys Asp Leu Leu Leu His Leu Lys Lys
Leu 50 55 60Phe Arg Glu Gly Gln Phe Asn Gly Gly Ser Gly Met Pro Gly
Pro Val65 70 75 80Pro Pro Ser Thr Ala Leu Arg Glu Leu Ile Glu Glu
Leu Val Asn Ile 85 90 95Thr Gln Asn Gln Lys Ala Pro Leu Cys Asn Gly
Ser Met Val Trp Ser 100 105 110Ile Asn Leu Thr Ala Gly
11512117PRTArtificial Sequencecircularly permuted IL-13 "A11"
variant 12Met Tyr Cys Ala Ala Leu Glu Ser Leu Ile Asn Val Ser Gly
Cys Ser1 5 10 15Ala Ile Glu Lys Thr Gln Arg Met Leu Ser Gly Phe Cys
Pro His Lys 20 25 30Val Ser Ala Gly Gln Phe Ser Ser Leu His Val Arg
Ser Ser Lys Ile 35 40 45Glu Val Ala Gln Phe Val Lys Asp Leu Leu Phe
His Leu Arg Thr Leu 50 55 60Phe Arg Glu Gly Gln Phe Asn Gly Gly Ser
Gly Pro Gly Pro Val Pro65 70 75 80Pro Ser Thr Ala Val Arg Glu Leu
Ile Glu Glu Leu Ile Asn Ile Thr 85 90 95Gln Asn Gln Lys Ala Pro Leu
Cys Asn Gly Ser Met Val Trp Ser Ile 100 105 110Asn Arg Thr Ala Gly
11513118PRTArtificial Sequencecircularly permuted IL-13 13Met Tyr
Cys Ala Ala Leu Glu Ser Leu Ile Asn Val Ser Gly Cys Ser1 5 10 15Ala
Ile Glu Lys Thr Gln Arg Met Leu Ser Gly Phe Cys Pro His Lys 20 25
30Val Ser Ala Gly Gln Phe Ser Ser Leu His Val Arg Ser Ser Lys Ile
35 40 45Glu Val Ala Gln Phe Val Lys Asp Leu Leu Phe His Leu Arg Thr
Leu 50 55 60Phe Arg Glu Gly Gln Phe Asn Gly Gly Ser Gly Met Pro Gly
Pro Val65 70 75 80Pro Pro Ser Thr Ala Val Arg Glu Leu Ile Glu Glu
Leu Ile Asn Ile 85 90 95Thr Gln Asn Gln Lys Ala Pro Leu Cys Asn Gly
Ser Met Val Trp Ser 100 105 110Ile Asn Arg Thr Ala Gly
11514117PRTArtificial Sequencecircularly permuted IL-13 "DN"
variant 14Met Tyr Cys Ala Ala Leu Glu Ser Leu Ile Asn Val Ser Gly
Cys Ser1 5 10 15Ala Ile Glu Lys Thr Gln Asp Met Leu Ser Gly Phe Cys
Pro His Lys 20 25 30Val Ser Ala Gly Gln Phe Ser Ser Leu His Val Arg
Ser Ser Lys Ile 35 40 45Glu Val Ala Gln Phe Val Lys Asp Leu Leu Phe
His Leu Arg Thr Leu 50 55 60Phe Arg Glu Gly Gln Phe Asn Gly Gly Ser
Gly Pro Gly Pro Val Pro65 70 75 80Pro Ser Thr Ala Val Arg Ala Leu
Ile Glu Glu Leu Ile Asn Ile Thr 85 90 95Gln Asn Gln Lys Ala Pro Leu
Cys Asn Gly Ser Met Val Trp Ser Ile 100 105 110Asn Leu Thr Ala Gly
11515118PRTArtificial Sequencecircular permuted IL-13 15Met Tyr Cys
Ala Ala Leu Glu Ser Leu Ile Asn Val Ser Gly Cys Ser1 5 10 15Ala Ile
Glu Lys Thr Gln Asp Met Leu Ser Gly Phe Cys Pro His Lys 20 25 30Val
Ser Ala Gly Gln Phe Ser Ser Leu His Val Arg Ser Ser Lys Ile 35 40
45Glu Val Ala Gln Phe Val Lys Asp Leu Leu Phe His Leu Arg Thr Leu
50 55 60Phe Arg Glu Gly Gln Phe Asn Gly Gly Ser Gly Met Pro Gly Pro
Val65 70 75 80Pro Pro Ser Thr Ala Val Arg Ala Leu Ile Glu Glu Leu
Ile Asn Ile 85 90 95Thr Gln Asn Gln Lys Ala Pro Leu Cys Asn Gly Ser
Met Val Trp Ser 100 105 110Ile Asn Leu Thr Ala Gly 11516167PRTHomo
sapiens 16Phe Gln Ile Pro Glu Phe Glu Pro Ser Glu Gln Glu Asp Ser
Ser Ser1 5 10 15Ala Glu Arg Gly Leu Gly Pro Ser Pro Ala Gly Asp Gly
Pro Ser Gly 20 25 30Ser Gly Lys His His Arg Gln Ala Pro Gly Leu Leu
Trp Asp Ala Ser 35 40 45His Gln Gln Glu Gln Pro Thr Ser Ser Ser His
His Gly Gly Ala Gly 50 55 60Ala Val Glu Ile Arg Ser Arg His Ser Ser
Tyr Pro Ala Gly Thr Glu65 70 75 80Asp Asp Glu Gly Met Gly Glu Glu
Pro Ser Pro Phe Arg Gly Arg Ser 85 90 95Arg Ala Ala Pro Pro Asn Leu
Trp Ala Ala Gln Arg Tyr Gly Arg Glu 100 105 110Leu Arg Arg Met Ser
Asp Glu Phe Val Asp Ser Phe Lys Lys Gly Leu 115 120 125Pro Arg Pro
Lys Ser Ala Gly Thr Ala Thr Gln Met Arg Gln Ser Ser 130 135 140Ser
Trp Thr Arg Val Phe Gln Ser Trp Trp Asp Arg Asn Leu Gly Arg145 150
155 160Gly Ser Ser Ala Pro Ser Gln 16517167PRTArtificial
Sequencevariant Bad 17Phe Gln Ile Pro Glu Phe Glu Pro Ser Glu Gln
Glu Asp Ser Ser Ser1 5 10 15Ala Glu Arg Gly Leu Gly Pro Ser Pro Ala
Gly Asp Gly Pro Ser Gly 20 25 30Ser Gly Lys His His Arg Gln Ala Pro
Gly Leu Leu Trp Asp Ala Ser 35 40 45His Gln Gln Glu Gln Pro Thr Ser
Ser Ser His His Gly Gly Ala Gly 50 55 60Ala Val Glu Ile Arg Ser Arg
His Ser Ala Tyr Pro Ala Gly Thr Glu65 70 75 80Asp Asp Glu Gly Met
Gly Glu Glu Pro Ser Pro Phe Arg Gly Arg Ser 85 90 95Arg Ala Ala Pro
Pro Asn Leu Trp Ala Ala Gln Arg Tyr Gly Arg Glu 100 105 110Leu Arg
Arg Met Ser Asp Glu Phe Val Asp Ser Phe Lys Lys Gly Leu 115 120
125Pro Arg Pro Lys Ser Ala Gly Thr Ala Thr Gln Met Arg Gln Ser Ser
130 135 140Ser Trp Thr Arg Val Phe Gln Ser Trp Trp Asp Arg Asn Leu
Gly Arg145 150 155 160Gly Ser Ser Ala Pro Ser Gln 16518167PRTHomo
sapiens 18Phe Gln Ile Pro Glu Phe Glu Pro Ser Glu Gln Glu Asp Ser
Ser Ser1 5 10 15Ala Glu Arg Gly Leu Gly Pro Ser Pro Ala Gly Asp Gly
Pro Ser Gly 20 25 30Ser Gly Lys His His Arg Gln Ala Pro Gly Leu Leu
Trp Asp Ala Ser 35 40 45His Gln Gln Glu Gln Pro Thr Ser Ser Ser His
His Gly Gly Ala Gly 50 55 60Ala Val Glu Ile Arg Ser Arg His Ser Ser
Tyr Pro Ala Gly Thr Glu65 70 75 80Asp Asp Glu Gly Met Gly Glu Glu
Pro Ser Pro Phe Arg Gly Arg Ser 85 90 95Arg Ser Ala Pro Pro Asn Leu
Trp Ala Ala Gln Arg Tyr Gly Arg Glu 100 105 110Leu Arg Arg Met Ser
Asp Glu Phe Val Asp Ser Phe Lys Lys Gly Leu 115 120 125Pro Arg Pro
Lys Ser Ala Gly Thr Ala Thr Gln Met Arg Gln Ser Ser 130 135 140Ser
Trp Thr Arg Val Phe Gln Ser Trp Trp Asp Arg Asn Leu Gly Arg145 150
155 160Gly Ser Ser Ala Pro Ser Gln 16519167PRTHomo sapiens 19Phe
Gln Ile Pro Glu Phe Glu Pro Ser Glu Gln Glu Asp Ser Ser Ser1 5
10 15Ala Glu Arg Gly Leu Gly Pro Ser Pro Ala Gly Asp Gly Pro Ser
Gly 20 25 30Ser Gly Lys His His Arg Gln Ala Pro Gly Leu Leu Trp Asp
Ala Ser 35 40 45His Gln Gln Glu Gln Pro Thr Ser Ser Ser His His Gly
Gly Ala Gly 50 55 60Ala Val Glu Ile Arg Ser Arg His Ser Ser Tyr Pro
Ala Gly Thr Glu65 70 75 80Asp Asp Glu Gly Met Gly Glu Glu Pro Ser
Pro Phe Arg Gly Arg Ser 85 90 95Arg Ser Ala Pro Pro Asn Leu Trp Ala
Ala Gln Arg Tyr Gly Arg Glu 100 105 110Leu Arg Arg Met Ser Asp Glu
Phe Val Asp Ser Phe Lys Lys Gly Leu 115 120 125Pro Arg Pro Lys Ser
Ala Gly Thr Ala Thr Gln Met Arg Gln Ser Ser 130 135 140Ser Trp Thr
Arg Val Phe Gln Ser Trp Trp Asp Arg Asn Leu Gly Arg145 150 155
160Gly Ser Ser Ala Pro Ser Gln 16520159PRTHomo sapiens 20Ser Glu
Val Arg Pro Leu Ser Arg Asp Ile Leu Met Glu Thr Leu Leu1 5 10 15Tyr
Glu Gln Leu Leu Glu Pro Pro Thr Met Glu Val Leu Gly Met Thr 20 25
30Asp Ser Glu Glu Asp Leu Asp Pro Met Glu Asp Phe Asp Ser Leu Glu
35 40 45Cys Met Glu Gly Ser Asp Ala Leu Ala Leu Arg Leu Ala Cys Ile
Gly 50 55 60Asp Glu Met Asp Val Ser Leu Arg Ala Pro Arg Leu Ala Gln
Leu Ser65 70 75 80Glu Val Ala Met His Ser Leu Gly Leu Ala Phe Ile
Tyr Asp Gln Thr 85 90 95Glu Asp Ile Arg Asp Val Leu Arg Ser Phe Met
Asp Gly Phe Thr Thr 100 105 110Leu Lys Glu Asn Ile Met Arg Phe Trp
Arg Ser Pro Asn Pro Gly Ser 115 120 125Trp Val Ser Cys Glu Gln Val
Leu Leu Ala Leu Leu Leu Leu Leu Ala 130 135 140Leu Leu Leu Pro Leu
Leu Ser Gly Gly Leu His Leu Leu Leu Lys145 150 15521194PRTHomo
sapiens 21Asp Cys Glu Val Asn Asn Gly Ser Ser Leu Arg Asp Glu Cys
Ile Thr1 5 10 15Asn Leu Leu Val Phe Gly Phe Leu Gln Ser Cys Ser Asp
Asn Ser Phe 20 25 30Arg Arg Glu Leu Asp Ala Leu Gly His Glu Leu Pro
Val Leu Ala Pro 35 40 45Gln Trp Glu Gly Tyr Asp Glu Leu Gln Thr Asp
Gly Asn Arg Ser Ser 50 55 60His Ser Arg Leu Gly Arg Ile Glu Ala Asp
Ser Glu Ser Gln Glu Asp65 70 75 80Ile Ile Arg Asn Ile Ala Arg His
Leu Ala Gln Val Gly Asp Ser Met 85 90 95Asp Arg Ser Ile Pro Pro Gly
Leu Val Asn Gly Leu Ala Leu Gln Leu 100 105 110Arg Asn Thr Ser Arg
Ser Glu Glu Asp Arg Asn Arg Asp Leu Ala Thr 115 120 125Ala Leu Glu
Gln Leu Leu Gln Ala Tyr Pro Arg Asp Met Glu Lys Glu 130 135 140Lys
Thr Met Leu Val Leu Ala Leu Leu Leu Ala Lys Lys Val Ala Ser145 150
155 160His Thr Pro Ser Leu Leu Arg Asp Val Phe His Thr Thr Val Asn
Phe 165 170 175Ile Asn Gln Asn Leu Arg Thr Tyr Val Arg Ser Leu Ala
Arg Asn Gly 180 185 190Met Asp22197PRTHomo sapiens 22Ala Lys Gln
Pro Ser Asp Val Ser Ser Glu Cys Asp Arg Glu Gly Arg1 5 10 15Gln Leu
Gln Pro Ala Glu Arg Pro Pro Gln Leu Arg Pro Gly Ala Pro 20 25 30Thr
Ser Leu Gln Thr Glu Pro Gln Gly Asn Pro Glu Gly Asn His Gly 35 40
45Gly Glu Gly Asp Ser Cys Pro His Gly Ser Pro Gln Gly Pro Leu Ala
50 55 60Pro Pro Ala Ser Pro Gly Pro Phe Ala Thr Arg Ser Pro Leu Phe
Ile65 70 75 80Phe Met Arg Arg Ser Ser Leu Leu Ser Arg Ser Ser Ser
Gly Tyr Phe 85 90 95Ser Phe Asp Thr Asp Arg Ser Pro Ala Pro Met Ser
Cys Asp Lys Ser 100 105 110Thr Gln Thr Pro Ser Pro Pro Cys Gln Ala
Phe Asn His Tyr Leu Ser 115 120 125Ala Met Ala Ser Met Arg Gln Ala
Glu Pro Ala Asp Met Arg Pro Glu 130 135 140Ile Trp Ile Ala Gln Glu
Leu Arg Arg Ile Gly Asp Glu Phe Asn Ala145 150 155 160Tyr Tyr Ala
Arg Arg Val Phe Leu Asn Asn Tyr Gln Ala Ala Glu Asp 165 170 175His
Pro Arg Met Val Ile Leu Arg Leu Leu Arg Tyr Ile Val Arg Leu 180 185
190Val Trp Arg Met His 1952389PRTHomo sapiens 23Cys Pro Cys Pro Leu
His Arg Gly Arg Gly Pro Pro Ala Val Cys Ala1 5 10 15Cys Ser Ala Gly
Arg Leu Gly Leu Arg Ser Ser Ala Ala Gln Leu Thr 20 25 30Ala Ala Arg
Leu Lys Ala Leu Gly Asp Glu Leu His Gln Arg Thr Met 35 40 45Trp Arg
Arg Arg Ala Arg Ser Arg Arg Ala Pro Ala Pro Gly Ala Leu 50 55 60Pro
Thr Tyr Trp Pro Trp Leu Cys Ala Ala Ala Gln Val Ala Ala Leu65 70 75
80Ala Ala Trp Leu Leu Gly Arg Arg Asn 8524297PRTArtificial
SequenceIL-4-Bad fusion 24Met His Lys Cys Asp Ile Thr Leu Gln Glu
Ile Ile Lys Thr Leu Asn1 5 10 15Ser Leu Thr Glu Gln Lys Thr Leu Cys
Thr Glu Leu Thr Val Thr Asp 20 25 30Ile Phe Ala Ala Ser Lys Asp Thr
Thr Glu Lys Glu Thr Phe Cys Arg 35 40 45Ala Ala Thr Val Leu Arg Gln
Phe Tyr Ser His His Glu Lys Asp Thr 50 55 60Arg Cys Leu Gly Ala Thr
Ala Gln Gln Phe His Arg His Lys Gln Leu65 70 75 80Ile Arg Phe Leu
Lys Arg Leu Asp Arg Asn Leu Trp Gly Leu Ala Gly 85 90 95Leu Asn Ser
Cys Pro Val Lys Glu Ala Asn Gln Ser Thr Leu Glu Asn 100 105 110Phe
Leu Glu Arg Leu Lys Thr Ile Met Arg Glu Lys Tyr Ser Lys Cys 115 120
125Ser Ser Phe Gln Ile Pro Glu Phe Glu Pro Ser Glu Gln Glu Asp Ser
130 135 140Ser Ser Ala Glu Arg Gly Leu Gly Pro Ser Pro Ala Gly Asp
Gly Pro145 150 155 160Ser Gly Ser Gly Lys His His Arg Gln Ala Pro
Gly Leu Leu Trp Asp 165 170 175Ala Ser His Gln Gln Glu Gln Pro Thr
Ser Ser Ser His His Gly Gly 180 185 190Ala Gly Ala Val Glu Ile Arg
Ser Arg His Ser Ala Tyr Pro Ala Gly 195 200 205Thr Glu Asp Asp Glu
Gly Met Gly Glu Glu Pro Ser Pro Phe Arg Gly 210 215 220Arg Ser Arg
Ala Ala Pro Pro Asn Leu Trp Ala Ala Gln Arg Tyr Gly225 230 235
240Arg Glu Leu Arg Arg Met Ser Asp Glu Phe Val Asp Ser Phe Lys Lys
245 250 255Gly Leu Pro Arg Pro Lys Ser Ala Gly Thr Ala Thr Gln Met
Arg Gln 260 265 270Ser Ser Ser Trp Thr Arg Val Phe Gln Ser Trp Trp
Asp Arg Asn Leu 275 280 285Gly Arg Gly Ser Ser Ala Pro Ser Gln 290
29525303PRTArtificial SequencecpIL4-Bad fusion 25Met Asp Thr Thr
Glu Lys Glu Thr Phe Cys Arg Ala Ala Thr Val Leu1 5 10 15Arg Gln Phe
Tyr Ser His His Glu Lys Asp Thr Arg Cys Leu Gly Ala 20 25 30Thr Ala
Gln Gln Phe His Arg His Lys Gln Leu Ile Arg Phe Leu Lys 35 40 45Arg
Leu Asp Arg Asn Leu Trp Gly Leu Ala Gly Leu Asn Ser Cys Pro 50 55
60Val Lys Glu Ala Asn Gln Ser Thr Leu Glu Asn Phe Leu Glu Arg Leu65
70 75 80Lys Thr Ile Met Arg Glu Lys Tyr Ser Lys Cys Ser Ser Gly Gly
Asn 85 90 95Gly Gly His Lys Cys Asp Ile Thr Leu Gln Glu Ile Ile Lys
Thr Leu 100 105 110Asn Ser Leu Thr Glu Gln Lys Thr Leu Cys Thr Glu
Leu Thr Val Thr 115 120 125Asp Ile Phe Ala Ala Ser Gly Ser Phe Gln
Ile Pro Glu Phe Glu Pro 130 135 140Ser Glu Gln Glu Asp Ser Ser Ser
Ala Glu Arg Gly Leu Gly Pro Ser145 150 155 160Pro Ala Gly Asp Gly
Pro Ser Gly Ser Gly Lys His His Arg Gln Ala 165 170 175Pro Gly Leu
Leu Trp Asp Ala Ser His Gln Gln Glu Gln Pro Thr Ser 180 185 190Ser
Ser His His Gly Gly Ala Gly Ala Val Glu Ile Arg Ser Arg His 195 200
205Ser Ala Tyr Pro Ala Gly Thr Glu Asp Asp Glu Gly Met Gly Glu Glu
210 215 220Pro Ser Pro Phe Arg Gly Arg Ser Arg Ala Ala Pro Pro Asn
Leu Trp225 230 235 240Ala Ala Gln Arg Tyr Gly Arg Glu Leu Arg Arg
Met Ser Asp Glu Phe 245 250 255Val Asp Ser Phe Lys Lys Gly Leu Pro
Arg Pro Lys Ser Ala Gly Thr 260 265 270Ala Thr Gln Met Arg Gln Ser
Ser Ser Trp Thr Arg Val Phe Gln Ser 275 280 285Trp Trp Asp Arg Asn
Leu Gly Arg Gly Ser Ser Ala Pro Ser Gln 290 295
30026303PRTArtificial SequencecpKFR4-Bad fusion 26Met Asp Thr Thr
Glu Lys Glu Thr Phe Cys Arg Ala Ala Thr Val Leu1 5 10 15Arg Gln Phe
Tyr Ser His His Glu Lys Asp Thr Arg Cys Leu Gly Ala 20 25 30Thr Ala
Gln Gln Phe His Arg His Lys Gln Leu Ile Arg Phe Leu Lys 35 40 45Arg
Leu Asp Arg Asn Leu Trp Gly Leu Ala Gly Leu Asn Ser Cys Pro 50 55
60Val Lys Glu Ala Asn Gln Ser Thr Leu Glu Asn Phe Leu Glu Arg Leu65
70 75 80Lys Thr Ile Met Lys Glu Lys Phe Arg Lys Cys Ser Ser Gly Gly
Asn 85 90 95Gly Gly His Lys Cys Asp Ile Thr Leu Gln Glu Ile Ile Lys
Thr Leu 100 105 110Asn Ser Leu Thr Glu Gln Lys Thr Leu Cys Thr Glu
Leu Thr Val Thr 115 120 125Asp Ile Phe Ala Ala Ser Gly Ser Phe Gln
Ile Pro Glu Phe Glu Pro 130 135 140Ser Glu Gln Glu Asp Ser Ser Ser
Ala Glu Arg Gly Leu Gly Pro Ser145 150 155 160Pro Ala Gly Asp Gly
Pro Ser Gly Ser Gly Lys His His Arg Gln Ala 165 170 175Pro Gly Leu
Leu Trp Asp Ala Ser His Gln Gln Glu Gln Pro Thr Ser 180 185 190Ser
Ser His His Gly Gly Ala Gly Ala Val Glu Ile Arg Ser Arg His 195 200
205Ser Ala Tyr Pro Ala Gly Thr Glu Asp Asp Glu Gly Met Gly Glu Glu
210 215 220Pro Ser Pro Phe Arg Gly Arg Ser Arg Ala Ala Pro Pro Asn
Leu Trp225 230 235 240Ala Ala Gln Arg Tyr Gly Arg Glu Leu Arg Arg
Met Ser Asp Glu Phe 245 250 255Val Asp Ser Phe Lys Lys Gly Leu Pro
Arg Pro Lys Ser Ala Gly Thr 260 265 270Ala Thr Gln Met Arg Gln Ser
Ser Ser Trp Thr Arg Val Phe Gln Ser 275 280 285Trp Trp Asp Arg Asn
Leu Gly Arg Gly Ser Ser Ala Pro Ser Gln 290 295
30027303PRTArtificial SequencecpS4-Bad fusion 27Met Asp Thr Thr Glu
Lys Glu Thr Phe Cys Arg Ala Ala Thr Val Leu1 5 10 15Arg Gln Phe Tyr
Ser His His Glu Lys Asp Thr Arg Cys Leu Gly Ala 20 25 30Thr Ala Gln
Gln Phe His Arg His Lys Gln Leu Ile Arg Phe Leu Lys 35 40 45Arg Leu
Asp Arg Asn Leu Trp Gly Leu Ala Gly Leu Asn Ser Cys Pro 50 55 60Val
Lys Glu Ala Asn Gln Ser Thr Leu Glu Asn Phe Leu Glu Arg Leu65 70 75
80Arg Val Ile Met Gln Ser Lys Trp Phe Lys Cys Gly Ala Gly Gly Asn
85 90 95Gly Gly His Lys Cys Asp Ile Thr Leu Gln Glu Ile Ile Lys Thr
Leu 100 105 110Asn Ser Leu Thr Glu Gln Lys Thr Leu Cys Thr Glu Leu
Thr Val Thr 115 120 125Asp Ile Phe Ala Ala Ser Gly Ser Phe Gln Ile
Pro Glu Phe Glu Pro 130 135 140Ser Glu Gln Glu Asp Ser Ser Ser Ala
Glu Arg Gly Leu Gly Pro Ser145 150 155 160Pro Ala Gly Asp Gly Pro
Ser Gly Ser Gly Lys His His Arg Gln Ala 165 170 175Pro Gly Leu Leu
Trp Asp Ala Ser His Gln Gln Glu Gln Pro Thr Ser 180 185 190Ser Ser
His His Gly Gly Ala Gly Ala Val Glu Ile Arg Ser Arg His 195 200
205Ser Ala Tyr Pro Ala Gly Thr Glu Asp Asp Glu Gly Met Gly Glu Glu
210 215 220Pro Ser Pro Phe Arg Gly Arg Ser Arg Ala Ala Pro Pro Asn
Leu Trp225 230 235 240Ala Ala Gln Arg Tyr Gly Arg Glu Leu Arg Arg
Met Ser Asp Glu Phe 245 250 255Val Asp Ser Phe Lys Lys Gly Leu Pro
Arg Pro Lys Ser Ala Gly Thr 260 265 270Ala Thr Gln Met Arg Gln Ser
Ser Ser Trp Thr Arg Val Phe Gln Ser 275 280 285Trp Trp Asp Arg Asn
Leu Gly Arg Gly Ser Ser Ala Pro Ser Gln 290 295
3002882PRTArtificial Sequenceubiquitin linker sequence 28Gly Gly
Gly Ser Met Gln Ile Phe Val Arg Thr Leu Thr Gly Arg Thr1 5 10 15Ile
Thr Leu Glu Val Glu Pro Ser Asp Thr Ile Glu Asn Val Arg Ala 20 25
30Arg Ile Gln Asp Arg Glu Gly Ile Pro Pro Asp Gln Gln Arg Leu Ile
35 40 45Phe Ala Gly Arg Gln Leu Glu Asp Gly Arg Thr Leu Ser Asp Tyr
Asn 50 55 60Ile Gln Arg Glu Ser Thr Leu His Leu Val Leu Arg Leu Arg
Gly Gly65 70 75 80Gly Ser296PRTArtificial Sequencelinker 29Ala Ser
Gly Gly Pro Glu1 530390DNAArtificial SequenceIL-4 30atgcacaaat
gcgacattac cctgcaagag atcattaaga ccctgaacag cctgaccgag 60caaaagaccc
tgtgtaccga actgaccgtc acggacatct tcgctgcgtc caaggacact
120acggaaaagg aaacgttctg tcgtgcggcg acggtgctgc gccagttcta
cagccaccat 180gagaaagata cccgttgcct cggtgcgacc gcgcaacagt
tccaccgtca caaacagctg 240attcgcttcc tgaagcgtct ggatcgcaac
ctgtggggtt tggcgggtct gaactcctgt 300ccagtcaaag aagccaatca
gtctacgctg gaaaactttt tggagcgtct gaaaactatc 360atgcgtgaga
agtacagcaa atgcagcagc 39031402DNAArtificial SequencecpIL4
31atggatacca ccgagaaaga aacgttctgc cgtgctgcca ctgtcctgcg ccagttttac
60agccatcacg aaaaggacac ccgttgcctg ggtgcgacgg cgcagcaatt ccaccgccac
120aaacagctga ttcgtttcct gaagcgtctg gaccgtaacc tgtggggtct
ggcgggtctg 180aacagctgtc cagtgaaaga agcgaatcag agcaccttgg
agaatttcct cgaacgcctg 240aaaaccatca tgcgtgagaa atacagcaag
tgttctagcg gcggtaacgg tggccacaaa 300tgcgatatca ccctgcaaga
gatcattaag acgctgaact ccttgacgga acaaaagacc 360ctgtgtactg
agctgacggt caccgacatt ttcgcggcgt cc 40232402DNAArtificial
SequencecpKFR 32atggatacta ccgagaaaga aacgttttgc cgtgctgcga
ccgtcctgcg tcagttctac 60agccaccacg aaaaggacac ccgctgtctg ggtgcgactg
cccaacaatt ccatcgtcac 120aaacagctga ttcgtttcct gaagcgtctg
gaccgcaacc tgtggggtct ggcgggcttg 180aactcctgcc cagtcaaaga
agcgaaccaa agcaccctgg aaaacttctt ggagcgtctg 240aaaacgatca
tgaaagagaa gttccgcaag tgtagcagcg gtggtaatgg tggccacaag
300tgcgacatta cgctgcagga aatcattaag accctgaact ctctgaccga
gcagaaaacc 360ctctgtaccg agctgacggt gacggatatc tttgcggcga gc
40233402DNAArtificial SequencecpS4 33atggatacca ccgaaaaaga
aactttttgt cgtgccgcga ctgtcctgcg ccagttctac 60agccaccacg aaaaggacac
ccgttgcctg ggtgcgaccg ctcaacaatt ccatcgccac 120aaacagctga
ttcgtttcct gaaacgtctg gatcgcaacc tgtggggtct ggcgggtttg
180aacagctgtc cagtcaaaga agcgaaccag agcaccctgg aaaactttct
ggagcgtctg 240cgtgttatca tgcagagcaa gtggttcaag tgcggtgcgg
gtggcaatgg tggccacaag 300tgtgacatta ccttgcaaga gattatcaaa
acgctgaact ctctgaccga gcaaaagacg 360ctgtgcaccg agctgacggt
gacggacatc ttcgcggcgt cc 40234507DNAArtificial
Sequencepro-apoptotic Bcl-2 family member nucleic acid molecule,
variant BAD 34ggtagctttc agatcccgga atttgagccg agcgagcaag
aggattcaag cagcgcggag 60cgcggtctgg gtccgagccc ggcaggcgac ggtccgagcg
gcagcggcaa gcatcaccgc 120caggcgccag gcctgctgtg ggatgcatcg
catcaacagg aacaaccgac gagcagcagc 180catcatggtg gcgctggtgc
ggttgagatt agatcgcgcc actccgcata tcctgccggc 240accgaagatg
acgaaggcat gggcgaggaa
ccgagcccgt tccgtggccg tagccgtgct 300gcaccgccga atctgtgggc
cgcacagcgt tatggtcgcg agttgcgtcg catgtccgac 360gagtttgttg
actccttcaa gaaaggttta ccgcgtccga aatctgccgg taccgcgacg
420cagatgcgtc agagcagcag ctggacccgc gtgtttcaat cttggtggga
tcgtaatctg 480ggtcgtggta gcagcgcacc gagccaa 50735897DNAArtificial
SequenceIL-4-Bad fusion 35atgcacaaat gcgacattac cctgcaagag
atcattaaga ccctgaacag cctgaccgag 60caaaagaccc tgtgtaccga actgaccgtc
acggacatct tcgctgcgtc caaggacact 120acggaaaagg aaacgttctg
tcgtgcggcg acggtgctgc gccagttcta cagccaccat 180gagaaagata
cccgttgcct cggtgcgacc gcgcaacagt tccaccgtca caaacagctg
240attcgcttcc tgaagcgtct ggatcgcaac ctgtggggtt tggcgggtct
gaactcctgt 300ccagtcaaag aagccaatca gtctacgctg gaaaactttt
tggagcgtct gaaaactatc 360atgcgtgaga agtacagcaa atgcagcagc
ggtagctttc agatcccgga atttgagccg 420agcgagcaag aggattcaag
cagcgcggag cgcggtctgg gtccgagccc ggcaggcgac 480ggtccgagcg
gcagcggcaa gcatcaccgc caggcgccag gcctgctgtg ggatgcatcg
540catcaacagg aacaaccgac gagcagcagc catcatggtg gcgctggtgc
ggttgagatt 600agatcgcgcc actccgcata tcctgccggc accgaagatg
acgaaggcat gggcgaggaa 660ccgagcccgt tccgtggccg tagccgtgct
gcaccgccga atctgtgggc cgcacagcgt 720tatggtcgcg agttgcgtcg
catgtccgac gagtttgttg actccttcaa gaaaggttta 780ccgcgtccga
aatctgccgg taccgcgacg cagatgcgtc agagcagcag ctggacccgc
840gtgtttcaat cttggtggga tcgtaatctg ggtcgtggta gcagcgcacc gagccaa
89736909DNAArtificial SequencecpIL4-Bad fusion 36atggatacca
ccgagaaaga aacgttctgc cgtgctgcca ctgtcctgcg ccagttttac 60agccatcacg
aaaaggacac ccgttgcctg ggtgcgacgg cgcagcaatt ccaccgccac
120aaacagctga ttcgtttcct gaagcgtctg gaccgtaacc tgtggggtct
ggcgggtctg 180aacagctgtc cagtgaaaga agcgaatcag agcaccttgg
agaatttcct cgaacgcctg 240aaaaccatca tgcgtgagaa atacagcaag
tgttctagcg gcggtaacgg tggccacaaa 300tgcgatatca ccctgcaaga
gatcattaag acgctgaact ccttgacgga acaaaagacc 360ctgtgtactg
agctgacggt caccgacatt ttcgcggcgt ccggtagctt tcagatcccg
420gaatttgagc cgagcgagca agaggattca agcagcgcgg agcgcggtct
gggtccgagc 480ccggcaggcg acggtccgag cggcagcggc aagcatcacc
gccaggcgcc aggcctgctg 540tgggatgcat cgcatcaaca ggaacaaccg
acgagcagca gccatcatgg tggcgctggt 600gcggttgaga ttagatcgcg
ccactccgca tatcctgccg gcaccgaaga tgacgaaggc 660atgggcgagg
aaccgagccc gttccgtggc cgtagccgtg ctgcaccgcc gaatctgtgg
720gccgcacagc gttatggtcg cgagttgcgt cgcatgtccg acgagtttgt
tgactccttc 780aagaaaggtt taccgcgtcc gaaatctgcc ggtaccgcga
cgcagatgcg tcagagcagc 840agctggaccc gcgtgtttca atcttggtgg
gatcgtaatc tgggtcgtgg tagcagcgca 900ccgagccaa 90937909DNAArtificial
SequencecpKFR4-Bad fusion 37atggatacta ccgagaaaga aacgttttgc
cgtgctgcga ccgtcctgcg tcagttctac 60agccaccacg aaaaggacac ccgctgtctg
ggtgcgactg cccaacaatt ccatcgtcac 120aaacagctga ttcgtttcct
gaagcgtctg gaccgcaacc tgtggggtct ggcgggcttg 180aactcctgcc
cagtcaaaga agcgaaccaa agcaccctgg aaaacttctt ggagcgtctg
240aaaacgatca tgaaagagaa gttccgcaag tgtagcagcg gtggtaatgg
tggccacaag 300tgcgacatta cgctgcagga aatcattaag accctgaact
ctctgaccga gcagaaaacc 360ctctgtaccg agctgacggt gacggatatc
tttgcggcga gcggtagctt tcagatcccg 420gaatttgagc cgagcgagca
agaggattca agcagcgcgg agcgcggtct gggtccgagc 480ccggcaggcg
acggtccgag cggcagcggc aagcatcacc gccaggcgcc aggcctgctg
540tgggatgcat cgcatcaaca ggaacaaccg acgagcagca gccatcatgg
tggcgctggt 600gcggttgaga ttagatcgcg ccactccgca tatcctgccg
gcaccgaaga tgacgaaggc 660atgggcgagg aaccgagccc gttccgtggc
cgtagccgtg ctgcaccgcc gaatctgtgg 720gccgcacagc gttatggtcg
cgagttgcgt cgcatgtccg acgagtttgt tgactccttc 780aagaaaggtt
taccgcgtcc gaaatctgcc ggtaccgcga cgcagatgcg tcagagcagc
840agctggaccc gcgtgtttca atcttggtgg gatcgtaatc tgggtcgtgg
tagcagcgca 900ccgagccaa 90938909DNAArtificial SequencecpS4-Bad
fusion 38atggatacca ccgaaaaaga aactttttgt cgtgccgcga ctgtcctgcg
ccagttctac 60agccaccacg aaaaggacac ccgttgcctg ggtgcgaccg ctcaacaatt
ccatcgccac 120aaacagctga ttcgtttcct gaaacgtctg gatcgcaacc
tgtggggtct ggcgggtttg 180aacagctgtc cagtcaaaga agcgaaccag
agcaccctgg aaaactttct ggagcgtctg 240cgtgttatca tgcagagcaa
gtggttcaag tgcggtgcgg gtggcaatgg tggccacaag 300tgtgacatta
ccttgcaaga gattatcaaa acgctgaact ctctgaccga gcaaaagacg
360ctgtgcaccg agctgacggt gacggacatc ttcgcggcgt ccggtagctt
tcagatcccg 420gaatttgagc cgagcgagca agaggattca agcagcgcgg
agcgcggtct gggtccgagc 480ccggcaggcg acggtccgag cggcagcggc
aagcatcacc gccaggcgcc aggcctgctg 540tgggatgcat cgcatcaaca
ggaacaaccg acgagcagca gccatcatgg tggcgctggt 600gcggttgaga
ttagatcgcg ccactccgca tatcctgccg gcaccgaaga tgacgaaggc
660atgggcgagg aaccgagccc gttccgtggc cgtagccgtg ctgcaccgcc
gaatctgtgg 720gccgcacagc gttatggtcg cgagttgcgt cgcatgtccg
acgagtttgt tgactccttc 780aagaaaggtt taccgcgtcc gaaatctgcc
ggtaccgcga cgcagatgcg tcagagcagc 840agctggaccc gcgtgtttca
atcttggtgg gatcgtaatc tgggtcgtgg tagcagcgca 900ccgagccaa
90939918DNAArtificial SequencecpIL-4-Bad 39atgcacaaat gcgacattac
cctgcaagag atcattaaga ccctgaacag cctgaccgag 60caaaagaccc tgtgtaccga
actgaccgtc acggacatct tcgctgcgtc caaggacact 120acggaaaagg
aaacgttctg tcgtgcggcg acggtgctgc gccagttcta cagccaccat
180gagaaagata cccgttgcct cggtgcgacc gcgcaacagt tccaccgtca
caaacagctg 240attcgcttcc tgaagcgtct ggatcgcaac ctgtggggtt
tggcgggtct gaactcctgt 300ccagtcaaag aagccaatca gtctacgctg
gaaaactttt tggagcgtct gaaaactatc 360atgcgtgaga agtacagcaa
atgcagcagc ggtagctttc agatcccgga atttgagccg 420agcgagcaag
aggattcaag cagcgcggag cgcggtctgg gtccgagccc ggcaggcgac
480ggtccgagcg gcagcggcaa gcatcaccgc caggcgccag gcctgctgtg
ggatgcatcg 540catcaacagg aacaaccgac gagcagcagc catcatggtg
gcgctggtgc ggttgagatt 600agatcgcgcc actccgcata tcctgccggc
accgaagatg acgaaggcat gggcgaggaa 660ccgagcccgt tccgtggccg
tagccgtgct gcaccgccga atctgtgggc cgcacagcgt 720tatggtcgcg
agttgcgtcg catgtccgac gagtttgttg actccttcaa gaaaggttta
780ccgcgtccga aatctgccgg taccgcgacg cagatgcgtc agagcagcag
ctggacccgc 840gtgtttcaat cttggtggga tcgtaatctg ggtcgtggta
gcagcgcacc gagccaacac 900caccatcacc atcactaa 91840305PRTArtificial
SequenceIL-4-Bad 40Met His Lys Cys Asp Ile Thr Leu Gln Glu Ile Ile
Lys Thr Leu Asn1 5 10 15Ser Leu Thr Glu Gln Lys Thr Leu Cys Thr Glu
Leu Thr Val Thr Asp 20 25 30Ile Phe Ala Ala Ser Lys Asp Thr Thr Glu
Lys Glu Thr Phe Cys Arg 35 40 45Ala Ala Thr Val Leu Arg Gln Phe Tyr
Ser His His Glu Lys Asp Thr 50 55 60Arg Cys Leu Gly Ala Thr Ala Gln
Gln Phe His Arg His Lys Gln Leu65 70 75 80Ile Arg Phe Leu Lys Arg
Leu Asp Arg Asn Leu Trp Gly Leu Ala Gly 85 90 95Leu Asn Ser Cys Pro
Val Lys Glu Ala Asn Gln Ser Thr Leu Glu Asn 100 105 110Phe Leu Glu
Arg Leu Lys Thr Ile Met Arg Glu Lys Tyr Ser Lys Cys 115 120 125Ser
Ser Gly Ser Phe Gln Ile Pro Glu Phe Glu Pro Ser Glu Gln Glu 130 135
140Asp Ser Ser Ser Ala Glu Arg Gly Leu Gly Pro Ser Pro Ala Gly
Asp145 150 155 160Gly Pro Ser Gly Ser Gly Lys His His Arg Gln Ala
Pro Gly Leu Leu 165 170 175Trp Asp Ala Ser His Gln Gln Glu Gln Pro
Thr Ser Ser Ser His His 180 185 190Gly Gly Ala Gly Ala Val Glu Ile
Arg Ser Arg His Ser Ala Tyr Pro 195 200 205Ala Gly Thr Glu Asp Asp
Glu Gly Met Gly Glu Glu Pro Ser Pro Phe 210 215 220Arg Gly Arg Ser
Arg Ala Ala Pro Pro Asn Leu Trp Ala Ala Gln Arg225 230 235 240Tyr
Gly Arg Glu Leu Arg Arg Met Ser Asp Glu Phe Val Asp Ser Phe 245 250
255Lys Lys Gly Leu Pro Arg Pro Lys Ser Ala Gly Thr Ala Thr Gln Met
260 265 270Arg Gln Ser Ser Ser Trp Thr Arg Val Phe Gln Ser Trp Trp
Asp Arg 275 280 285Asn Leu Gly Arg Gly Ser Ser Ala Pro Ser Gln His
His His His His 290 295 300His30541927DNAArtificial Sequencebp
cpIL-4-Bad 41atggatacca ccgagaaaga aacgttctgc cgtgctgcca ctgtcctgcg
ccagttttac 60agccatcacg aaaaggacac ccgttgcctg ggtgcgacgg cgcagcaatt
ccaccgccac 120aaacagctga ttcgtttcct gaagcgtctg gaccgtaacc
tgtggggtct ggcgggtctg 180aacagctgtc cagtgaaaga agcgaatcag
agcaccttgg agaatttcct cgaacgcctg 240aaaaccatca tgcgtgagaa
atacagcaag tgttctagcg gcggtaacgg tggccacaaa 300tgcgatatca
ccctgcaaga gatcattaag acgctgaact ccttgacgga acaaaagacc
360ctgtgtactg agctgacggt caccgacatt ttcgcggcgt ccggtagctt
tcagatcccg 420gaatttgagc cgagcgagca agaggattca agcagcgcgg
agcgcggtct gggtccgagc 480ccggcaggcg acggtccgag cggcagcggc
aagcatcacc gccaggcgcc aggcctgctg 540tgggatgcat cgcatcaaca
ggaacaaccg acgagcagca gccatcatgg tggcgctggt 600gcggttgaga
ttagatcgcg ccactccgca tatcctgccg gcaccgaaga tgacgaaggc
660atgggcgagg aaccgagccc gttccgtggc cgtagccgtg ctgcaccgcc
gaatctgtgg 720gccgcacagc gttatggtcg cgagttgcgt cgcatgtccg
acgagtttgt tgactccttc 780aagaaaggtt taccgcgtcc gaaatctgcc
ggtaccgcga cgcagatgcg tcagagcagc 840agctggaccc gcgtgtttca
atcttggtgg gatcgtaatc tgggtcgtgg tagcagcgca 900ccgagccaac
accaccatca ccatcac 92742309PRTArtificial SequencecpIL-4-Bad 42Met
Asp Thr Thr Glu Lys Glu Thr Phe Cys Arg Ala Ala Thr Val Leu1 5 10
15Arg Gln Phe Tyr Ser His His Glu Lys Asp Thr Arg Cys Leu Gly Ala
20 25 30Thr Ala Gln Gln Phe His Arg His Lys Gln Leu Ile Arg Phe Leu
Lys 35 40 45Arg Leu Asp Arg Asn Leu Trp Gly Leu Ala Gly Leu Asn Ser
Cys Pro 50 55 60Val Lys Glu Ala Asn Gln Ser Thr Leu Glu Asn Phe Leu
Glu Arg Leu65 70 75 80Lys Thr Ile Met Arg Glu Lys Tyr Ser Lys Cys
Ser Ser Gly Gly Asn 85 90 95Gly Gly His Lys Cys Asp Ile Thr Leu Gln
Glu Ile Ile Lys Thr Leu 100 105 110Asn Ser Leu Thr Glu Gln Lys Thr
Leu Cys Thr Glu Leu Thr Val Thr 115 120 125Asp Ile Phe Ala Ala Ser
Gly Ser Phe Gln Ile Pro Glu Phe Glu Pro 130 135 140Ser Glu Gln Glu
Asp Ser Ser Ser Ala Glu Arg Gly Leu Gly Pro Ser145 150 155 160Pro
Ala Gly Asp Gly Pro Ser Gly Ser Gly Lys His His Arg Gln Ala 165 170
175Pro Gly Leu Leu Trp Asp Ala Ser His Gln Gln Glu Gln Pro Thr Ser
180 185 190Ser Ser His His Gly Gly Ala Gly Ala Val Glu Ile Arg Ser
Arg His 195 200 205Ser Ala Tyr Pro Ala Gly Thr Glu Asp Asp Glu Gly
Met Gly Glu Glu 210 215 220Pro Ser Pro Phe Arg Gly Arg Ser Arg Ala
Ala Pro Pro Asn Leu Trp225 230 235 240Ala Ala Gln Arg Tyr Gly Arg
Glu Leu Arg Arg Met Ser Asp Glu Phe 245 250 255Val Asp Ser Phe Lys
Lys Gly Leu Pro Arg Pro Lys Ser Ala Gly Thr 260 265 270Ala Thr Gln
Met Arg Gln Ser Ser Ser Trp Thr Arg Val Phe Gln Ser 275 280 285Trp
Trp Asp Arg Asn Leu Gly Arg Gly Ser Ser Ala Pro Ser Gln His 290 295
300His His His His His30543930DNAArtificial Sequencebp cpS4-Bad
43atggatacca ccgaaaaaga aactttttgt cgtgccgcga ctgtcctgcg ccagttctac
60agccaccacg aaaaggacac ccgttgcctg ggtgcgaccg ctcaacaatt ccatcgccac
120aaacagctga ttcgtttcct gaaacgtctg gatcgcaacc tgtggggtct
ggcgggtttg 180aacagctgtc cagtcaaaga agcgaaccag agcaccctgg
aaaactttct ggagcgtctg 240cgtgttatca tgcagagcaa gtggttcaag
tgcggtgcgg gtggcaatgg tggccacaag 300tgtgacatta ccttgcaaga
gattatcaaa acgctgaact ctctgaccga gcaaaagacg 360ctgtgcaccg
agctgacggt gacggacatc ttcgcggcgt ccggtagctt tcagatcccg
420gaatttgagc cgagcgagca agaggattca agcagcgcgg agcgcggtct
gggtccgagc 480ccggcaggcg acggtccgag cggcagcggc aagcatcacc
gccaggcgcc aggcctgctg 540tgggatgcat cgcatcaaca ggaacaaccg
acgagcagca gccatcatgg tggcgctggt 600gcggttgaga ttagatcgcg
ccactccgca tatcctgccg gcaccgaaga tgacgaaggc 660atgggcgagg
aaccgagccc gttccgtggc cgtagccgtg ctgcaccgcc gaatctgtgg
720gccgcacagc gttatggtcg cgagttgcgt cgcatgtccg acgagtttgt
tgactccttc 780aagaaaggtt taccgcgtcc gaaatctgcc ggtaccgcga
cgcagatgcg tcagagcagc 840agctggaccc gcgtgtttca atcttggtgg
gatcgtaatc tgggtcgtgg tagcagcgca 900ccgagccaac accaccatca
ccatcactaa 93044309PRTArtificial SequencecpS4-Bad 44Met Asp Thr Thr
Glu Lys Glu Thr Phe Cys Arg Ala Ala Thr Val Leu1 5 10 15Arg Gln Phe
Tyr Ser His His Glu Lys Asp Thr Arg Cys Leu Gly Ala 20 25 30Thr Ala
Gln Gln Phe His Arg His Lys Gln Leu Ile Arg Phe Leu Lys 35 40 45Arg
Leu Asp Arg Asn Leu Trp Gly Leu Ala Gly Leu Asn Ser Cys Pro 50 55
60Val Lys Glu Ala Asn Gln Ser Thr Leu Glu Asn Phe Leu Glu Arg Leu65
70 75 80Arg Val Ile Met Gln Ser Lys Trp Phe Lys Cys Gly Ala Gly Gly
Asn 85 90 95Gly Gly His Lys Cys Asp Ile Thr Leu Gln Glu Ile Ile Lys
Thr Leu 100 105 110Asn Ser Leu Thr Glu Gln Lys Thr Leu Cys Thr Glu
Leu Thr Val Thr 115 120 125Asp Ile Phe Ala Ala Ser Gly Ser Phe Gln
Ile Pro Glu Phe Glu Pro 130 135 140Ser Glu Gln Glu Asp Ser Ser Ser
Ala Glu Arg Gly Leu Gly Pro Ser145 150 155 160Pro Ala Gly Asp Gly
Pro Ser Gly Ser Gly Lys His His Arg Gln Ala 165 170 175Pro Gly Leu
Leu Trp Asp Ala Ser His Gln Gln Glu Gln Pro Thr Ser 180 185 190Ser
Ser His His Gly Gly Ala Gly Ala Val Glu Ile Arg Ser Arg His 195 200
205Ser Ala Tyr Pro Ala Gly Thr Glu Asp Asp Glu Gly Met Gly Glu Glu
210 215 220Pro Ser Pro Phe Arg Gly Arg Ser Arg Ala Ala Pro Pro Asn
Leu Trp225 230 235 240Ala Ala Gln Arg Tyr Gly Arg Glu Leu Arg Arg
Met Ser Asp Glu Phe 245 250 255Val Asp Ser Phe Lys Lys Gly Leu Pro
Arg Pro Lys Ser Ala Gly Thr 260 265 270Ala Thr Gln Met Arg Gln Ser
Ser Ser Trp Thr Arg Val Phe Gln Ser 275 280 285Trp Trp Asp Arg Asn
Leu Gly Arg Gly Ser Ser Ala Pro Ser Gln His 290 295 300His His His
His His30545926DNAArtificial Sequencebp pKFR4-Bad-H6 45atggatacta
ccgagaaaga aacgttttgc cgtgctgcga ccgtcctgcg tcagttctac 60agccaccacg
aaaaggacac ccgctgtctg ggtgcgactg cccaacaatt ccatcgtcac
120aaacagctga ttcgtttcct gaagcgtctg gaccgcaacc tgtggggtct
ggcgggcttg 180aactcctgcc cagtcaaaga agcgaaccaa agcaccctgg
aaaacttctt ggagcgtctg 240aaaacgatca tgaaagagaa gttccgcaag
tgtagcagcg gtggtaatgg tggccacaag 300tgcgacatta cgctgcagga
aatcattaag accctgaact ctctgaccga gcagaaaacc 360ctctgtaccg
agctgacggt gacggatatc tttgcggcga gcggtagctt tcagatcccg
420gaatttgagc cgagcgagca agaggattca agcagcgcgg agcgcggtct
gggtccgagc 480ccggcaggcg acggtccgag cggcagcggc aagcatcacc
gccaggcgcc aggcctgctg 540tgggatgcat cgcatcaaca ggaacaaccg
acgagcagca gccatcatgg tggcgctggt 600gcggttgaga ttagatcgcg
ccactccgca tatcctgccg gcaccgaaga tgacgaaggc 660atgggcgagg
aaccgagccc gttccgtggc cgtagccgtg ctgcaccgcc gaatctgtgg
720gccgcacagc gttatggtcg cgagttgcgt cgcatgtccg acgagtttgt
tgactccttc 780aagaaaggtt taccgcgtcc gaaatctgcc ggtaccgcga
cgcagatgcg tcagagcagc 840agctggaccc gcgtgtttca atcttggtgg
gatcgtaatc tgggtcgtgg tagcagcgca 900ccgagccaac accaccatca ccatca
92646309PRTArtificial SequencepKFR4-Bad-H6 46Met Asp Thr Thr Glu
Lys Glu Thr Phe Cys Arg Ala Ala Thr Val Leu1 5 10 15Arg Gln Phe Tyr
Ser His His Glu Lys Asp Thr Arg Cys Leu Gly Ala 20 25 30Thr Ala Gln
Gln Phe His Arg His Lys Gln Leu Ile Arg Phe Leu Lys 35 40 45Arg Leu
Asp Arg Asn Leu Trp Gly Leu Ala Gly Leu Asn Ser Cys Pro 50 55 60Val
Lys Glu Ala Asn Gln Ser Thr Leu Glu Asn Phe Leu Glu Arg Leu65 70 75
80Lys Thr Ile Met Lys Glu Lys Phe Arg Lys Cys Ser Ser Gly Gly Asn
85 90 95Gly Gly His Lys Cys Asp Ile Thr Leu Gln Glu Ile Ile Lys Thr
Leu 100 105 110Asn Ser Leu Thr Glu Gln Lys Thr Leu Cys Thr Glu Leu
Thr Val Thr 115 120 125Asp Ile Phe Ala Ala Ser Gly Ser Phe Gln Ile
Pro Glu Phe Glu Pro 130 135 140Ser Glu Gln Glu Asp Ser Ser Ser Ala
Glu Arg Gly Leu Gly Pro Ser145 150 155 160Pro Ala Gly Asp Gly Pro
Ser Gly Ser Gly Lys His His Arg Gln Ala 165 170 175Pro Gly Leu Leu
Trp Asp Ala Ser His Gln Gln Glu Gln Pro Thr Ser 180
185 190Ser Ser His His Gly Gly Ala Gly Ala Val Glu Ile Arg Ser Arg
His 195 200 205Ser Ala Tyr Pro Ala Gly Thr Glu Asp Asp Glu Gly Met
Gly Glu Glu 210 215 220Pro Ser Pro Phe Arg Gly Arg Ser Arg Ala Ala
Pro Pro Asn Leu Trp225 230 235 240Ala Ala Gln Arg Tyr Gly Arg Glu
Leu Arg Arg Met Ser Asp Glu Phe 245 250 255Val Asp Ser Phe Lys Lys
Gly Leu Pro Arg Pro Lys Ser Ala Gly Thr 260 265 270Ala Thr Gln Met
Arg Gln Ser Ser Ser Trp Thr Arg Val Phe Gln Ser 275 280 285Trp Trp
Asp Arg Asn Leu Gly Arg Gly Ser Ser Ala Pro Ser Gln His 290 295
300His His His His His305475PRTArtificial Sequencelinker 47Gly Gly
Asn Gly Gly1 5
* * * * *